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Abstract 
 
 Omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) blood levels are a potential 
risk factor for coronary heart disease, particularly sudden cardiac death. Venipuncture sampling 
for fatty acid profiling is invasive, requires highly qualified personnel and requires a multi-step 
protocol to isolate blood fractions. Alternately, the use of whole blood for fatty acid profiling 
improves analytical throughput and allows sample collection in field research locations by 
enabling dried blood spotting (DBS). Dried blood spots are advantageous in comparison to venous 
blood sampling as they require small blood volumes and is relatively inexpensive to collect. 
However, FA profiles in DBS are commonly expressed qualitatively (% of total fatty acids) and 
not quantitatively (µg/mL) as finger-tip prick (FTP) sampling usually results in the collection of 
an unknown volume of blood. Quantitation can be effected by preexisting fatty acid contaminants 
on DBS collection materials and oxidative losses of sensitive fatty acids such as n-3 LCPUFA due 
to the increased surface area of DBS samples. Fatty acid quantitation could detect hypo- and hyper-
lipidemia in samples that a qualitative only assessments would miss. To address these issues, the 
relationship between blood volume and blood spot area on 903 Protein Saver Cards (903 PSC) 
was examined to determine the blood volume associated with a 6mm hole punch and the Mitra 
Microsampling Device, a product designed to collect 10 µL of blood regardless of hematocrit, was 
assessed for FA and lipidomic analyses.  To determine if fatty acid contaminants were present, the 
903 PSC, the Mitra tips and Whatman chromatography paper (also commonly used to collect blood 
spots) were examined using gas chromatography and ultra high-performance liquid 
chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS). Finally, the stability 
of the fatty acids in a DBS sample on Mitra and 903 PSC stored at ambient, 4C, -20C and -80C 
temperatures with and without antioxidant for 3 months was examined.  It was determined that the 
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6mm punch of 903 PSC contained 9.6 µL of blood and that FA profiles determined from the Mitra 
samples were comparable to FA profiles from wet blood controls.  The Mitra tips could also be 
used to provide similar lipidomic profiles.  The 903 PSC, the Mitra tips and the Whatman paper 
all contained palmitic and stearic acid as free fatty acids (FFA) while the Mitra tips also had 
palmitoyl and stearoyl lysophosphatidylcholines (LysoPC) present. With DBS storage, the n-3 
LCPUFA biomarkers were the most stable with -80C storage followed by 4C or ambient room 
temperatures while samples stored at -20C storage had the lowest stability in both antioxidant and 
no antioxidant conditions, which mirrored previous research examining whole blood storage.  In 
conclusion, quantitative fatty acid determinations of DBS samples are possible.  Blood volumes 
can be estimated using a defined hole punch on the commonly used 903 PSC, or defined by using 
a Mitra sampling device.  Analysis of blank sampling devices is recommended to assess the 
potential impact of fatty acid and fatty acyl contaminants in any DBS collection materials to be 
used.  Finally, storage conditions need to be a consideration with DBS sample collection as 
preventative steps such as storage temperature and the use of antioxidants can improve sample 
stability and ensure data integrity.  
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Chapter 1 
 
Introduction 
 
 The omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) are linked to reduced risk of cardiovascular disease 
(CVD) [1], infant neurodevelopment [2] and health [3]. Omega-3 blood biomarkers such as the 
omega-3 index (sum of the percentages of EPA and DHA in total fatty acids of erythrocytes), have 
been characterized in the global population [4] and allowed for the development of blood level 
targets to optimize cardio-protective effects [5]. Recently, it has been demonstrated that maternal 
EPA+DHA status during pregnancy is associated with the risk of the infant developing asthma 
after birth [3]. Thus, screening blood for fatty acid (FA) health biomarkers in various populations 
has clinical utility in preventing morbidity and reducing health care costs.  
One of the challenges with fatty acid profiling of blood samples is the lack of consensus in 
analytical procedures [4, 6]. This includes different blood fractions, with plasma total lipids, 
plasma phospholipids and erythrocytes being examined typically.  Recently, whole blood sampling 
has emerged as an option, because it can simplify sample collection as it can be accessed through 
procedures such as finger-tip prick (FTP) or heel prick to generate dried blood spot (DBS) samples 
[7]. DBS have logistical and economic advantages in the collection, handling and storage of 
samples in various clinical and field research settings because they do not require the same amount 
of infrastructure and highly qualified personnel as compared with venipuncture and blood 
fractioning methods. DBS can provide informative fatty acid profiles [6] and have been used to 
assess mothers and newborns [8, 9], Zimbabwean children [10], young Canadians [11] and Tibetan 
adults [12]. In comparison to whole blood sampling however, DBS samples have limitations as 
quantitative (ex. µg/mL) results are not possible unless; blood volumes were assessed prior to 
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spotting, any fatty acid (FA) contaminants present on materials commonly used to spot the blood 
are determined, and the high risk of PUFA loss during storage is properly managed [13]. 
Currently in the literature, FA determinations from DBS samples have mainly been 
expressed qualitatively, which is the percentage of an individual fatty acid in the total fatty acids 
[10, 14, 15].  This is the most common method of presenting fatty acid data [4]  as it highlights the 
metabolic competition between fatty acids within pools of complex lipids and most blood 
biomarkers are based on these qualitative measurements.  For example, the sum of the weight 
percent (wt %) of EPA and DHA [16] and the percentage of omega-3 highly unsaturated fatty 
acids (HUFA) in total HUFA [17] are both qualitative assessments. However, qualitative 
assessments result in a lack of independence of the data as increases in one fatty acid are reflected 
by a decrease in another because they are expressed in relative abundance (% of total FA). 
Qualitative FA profiles also may remain blind to variations in total fat concentration that may be 
caused by recent food consumption, dietary habits, age, gender and genetic background [18]. 
Internal fatty acid standards are available and gas chromatography responses are robust, so precise 
quantitative determinations are possible, but the volume of blood collected by DBS is not usually 
measured.  
This thesis examines quantitation of fatty acid profiles of DBS on two commercially 
available products. First, a method will be developed to determine unknown volumes of blood on 
903 Protein Saver Cards (903 PSC) which are one of the most commonly used DBS materials for 
clinical blood collections. Second, a novel microsampling device, Mitra® will be validated for FA 
analysis. The Mitra uses absorptive technology to wick 10 μL of sample regardless of viscosity 
which can be influenced by hematocrit level in blood. 
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This thesis will also examine FA contaminants in materials used to collect DBS as they 
can also impact quantitative efforts.   Palmitate (C 16:0) and stearate (C18:0) contamination 
appears to be common in various chromatography papers used to collect blood samples [19]. 
Again, the focus will be on the 903 PSC and the Mitra, as these are materials specifically designed 
to collect DBS.  In addition to using gas chromatography (GC) to identify if fatty acids are present, 
we will also examine the lipid extractions with ultra-high performance liquid chromatography 
coupled with tandem mass spectrometry (UHPLC-MS/MS) to determine if the fatty acids are 
present as free fatty acids or as fatty acyls within a complex lipid. UHPLC-MS/MS will also be 
used to assess lipidomic profiles in Mitra tips using traditional collection materials.  
Finally, given that sample storage can result in losses in PUFA [13] and impact 
quantitation, the effect of storage of DBS on 903 PSC and Mitra on fatty acid profiles will be 
determined.  Practical fatty acid storage conditions will be examined and include ambient room 
temperature, 4C, -20C and -75C temperatures. The ambient, 4C, -20C may provide 
information on means of storage when access to the optimal ultra-cold storage (-75C) is not 
possible, but when a common household refrigerator and/or regular freezer are available. The use 
of antioxidants to improve FA stability in DBS on 903 PSC and Mitra will also be assessed given 
previous reports of improved FA stability of DBS samples on chromatography paper[15, 20].  
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Chapter 2 
Background 
2.1 Blood Fatty Acids as Biomarkers of Diet and Health  
 Fatty acids in blood have been used as an assessment tool for determining risk levels for 
chronic disease, cardiovascular disease, cognitive decline and as markers of dietary fat intake [7]. 
The omega-3 index, the sum of the percentages of EPA and DHA in erythrocytes is a risk factor 
for coronary heart disease or sudden cardiac death because of the role the n-3 FAs have in 
membranes and their interaction with membrane bound proteins [16]. Increased levels of EPA and 
DHA dietary intake has demonstrated positive health benefits in instances of neurological 
development in preterm infants [21, 22], rheumatoid arthritis [23], depressive disorder [24], 
inflammation [25] and cardiovascular disorders [26]. Therefore, some health agencies have 
recommended increasing n-3 intake through diet or supplementation to reduce disease risk and 
improve the health of the general population [27, 28]. Dietary recommendations can be made based 
on blood FA levels as a linear correlation between EPA + DHA intake and n-3 FA blood 
biomarkers through tightly controlled dietary intake trials and the relationship has been observed 
in whole blood, RBC and plasma phospholipid pools [29].  
 
2.2 Blood Fatty Acid Analysis: Blood Fractions and Lipid Pool Considerations 
Fatty acid profiles can either be expressed for whole blood or for common blood fractions 
of erythrocytes or red blood cells (RBC), plasma, and/or buffy coat. Plasma fatty acid profiles can 
be presented as the fatty acid composition of total lipids or as the composition of lipid subclasses 
such as phospholipids, triacylglycerols (TAG), and cholesteryl esters.  While the fatty acid 
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compositions of these different blood pools can predict the composition of the other blood pools 
[6], each blood/lipid pool can be influenced by diet and metabolism differently. 
Plasma fatty acid composition mainly reflects the fatty acyls of lipids in lipoproteins [30] 
with some contribution from the nonesterified fatty acid pool [18]. The lipoproteins consist of a 
monolayer of phospholipids that is largely of the phosphatidylcholine species with cholesterol and 
apolipoproteins.  This results in a spherical particle with a nonpolar core of largely TAG and 
cholesteryl esters.  Based on their relative densities dictated by the ratio of triacylglycerol to protein 
content, plasma lipoproteins can be classified as chylomicrons (CM), very-low-density 
lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL). 
However, the lipoprotein classes can further be separated into intermediate-density lipoproteins 
(IDL) and subclasses of HDL lipoproteins including HDL1, HDL2, HDL3 and so on which have 
different functions based on their structure [31]. Lipoprotein classification can be attributed to their 
main metabolic functions; chylomicrons and VLDL transport TAGs from the intestine or liver to 
peripheral tissues and alternately, HDL removes excess cholesterol and transports it to the liver to 
be excreted. Thus, lipoproteins play an important role in TAG and cholesterol metabolism. 
Specifically, the hydrophobic tendencies of TAG molecules require lipoproteins for transport in 
the aqueous plasma. TAG molecules generally exist in enantiomeric forms and their FA 
composition represents recent dietary intake from preceding days. The fatty acid composition of 
TAG tends to be dominated by saturated fatty acids (SFA) and monounsaturated fatty acids 
(MUFA), specifically C 16:0, C 18:0, and C 18:1 but also contains C 18:2n-6 which is high in the 
diet of industrialized countries as well its’ primary metabolite, C 20:4n-6 [18].  Fatty acid 
composition data on isolated types of lipoproteins is rare due to tedious separation techniques 
required, whereas lipid class isolation is more common as it can be achieved with thin layer 
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chromatography.  The nonesterified fatty acid pool is largely maintained by lipolysis of TAG stores 
within adipose tissue although dietary fatty acids can contribute to the pool post absorption via 
lipoprotein lipase spillover [18]. In general, of the total fatty acids in plasma, 44-59% are 
associated with TAG, 24-31% associated with PL, 14-21% associated with CE, and 3-6% as NEFA 
[18]. 
 Erythrocytes or RBCs are mainly plasma membranes containing hemoglobin.  As such, 
their fatty acids are found predominantly as fatty acyls of phospholipids (PL). As the membrane 
is a lipid bilayer, it is composed of phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI) and sphingomyelin (SPH) [18].  Each class of 
PL can have a characteristic fatty acid composition but they generally have a SFA/MUFA in the 
sn-1 position and a MUFA/PUFA in the sn-2 position [18].  RBC fatty acid profiles are often 
promoted as a better marker of long term dietary habits based on the 3-month half-life of 
erythrocytes.  However, it has been shown that the fatty acid profile of RBC membranes can 
remodel relatively quickly in response to dietary changes [32].  This remodeling may be specific 
to the outer layer and PC, while inner membrane phospholipids such as PE may take longer to 
remodel [32].  This has been demonstrated to have an effect on how we interpret omega-3 
biomarkers as EPA appears to have a higher remodeling rate compared with DHA [7].  The 
erythrocyte fatty acid profile can be correlated with plasma fatty acids, although there is 
considerably less C 18:1n-9 and C 18:2n-6 as these are typically high in the TAG pool absent in 
RBC [6, 33]. 
The buffy coat is collected less frequently, but the FA profiles tend to be similar to RBC.  
This is largely because the buffy coat fatty acids are predominantly from the lipid bilayers of white 
blood cells and platelets [18]. However, the size of the buffy coat fraction can vary in size within 
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and between individuals due to various immune conditions and responses.  The impact of changes 
in the buffy coat on fatty acid composition have not be examined in detail.  
Blood fractioning into plasma, RBC and WBC requires a venous blood draw, anticoagulant 
to prevent RBC lysis and a centrifuge which may not be accessible outside of an analytical facility. 
Thus, whole blood sampling is an attractive alternative for epidemiological studies because it 
enables microsampling procedures such as finger-tip prick or heel prick DBS collections [7]. The 
accessibility, low volume collection, simple sample processing and storage options for DBS makes 
it an attractive option for large screening studies or field related blood collections.  DBS samples 
are, however, a combination of all blood fractions, so the advantages and disadvantages of all the 
fractions are combined.  In being a comprehensive sample, detailed mechanistic insights from the 
FA composition of DBS can therefore be limited, but the comprehensive approach also means that 
no fatty acid information of a specific lipid pool has been lost. 
 
2.3 Dried Blood Spotting and the Growth of Whole Blood Microsampling for Fatty Acid 
Analyses 
 DBS have commonly been used in field research due to the advantages they have in 
collection, storage and transport in comparison to handling wet blood. DBS requires ~50 L or 
less of blood per spot and enables relatively non-invasive and repeatable FTP or heel prick 
collection procedures. DBS were originally used to test for phenlyketoneuria in neonates in the 
1960s and has broadened its scope towards HIV testing and now is commonly used for FA 
profiling in humans [34]. Advancements in the sensitivity of mass spectrometry and gas 
chromatography means that very low volumes of blood can be used for meaningful analyses 
(~10-20 L). 
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DBS in comparison to standard venous blood sampling has lower risks due to its non-
invasive blood sampling protocol such that venous blood draws may raise ethical concerns in the 
elderly, infants or other populations. FTP sampling also allows multiple collections within short 
periods of time which is not possible with venous blood sampling [7]. However, FTP sampling 
methods collect unpredictable volumes of blood and can only be expressed qualitatively as percent 
of total fatty acids identified (%TFA). Differences in FAs when expressing data in %TFA can be 
dictated by increases or decreases in other FAs, which may mask the true quantitative response.  
This is particularly problematic when considering circumstances that may introduce variation in 
the total FA pool such as lipid disorders, postprandial responses or other environmental and genetic 
factors. Alternately, FA profiles can be expressed quantitatively as microgram of fatty acid per 
milliliter of blood (μg FA/ mL blood) if the volume of sample is known. FA quantitation can give 
insight into fluctuations in total concentrations and changes in individual FAs are much easier to 
identify because the variability in the profiles is more visible. Additionally, to truly consider 
factors that may influence DBS FA quantitation, FA contaminants present on dried blood spotting 
materials should also be considered. 
Palmitate and stearate fatty acid contaminants have been identified on commonly used 
spotting materials [19]. Contaminants are included in FA determinations as they are methylated 
with the biological sample during chemical preparations. “Washing” chromatography papers in 
acetone or a methylating agent has been used to remove FA contaminants on blank spotting 
materials [35] but certain product designs include inks and other cosmetic features that may 
saturate into the blood spotting area. Lui et al. recently identified FA contaminants on the Fluka 
blood collection kit, Hemaspot-80 blood collection paper, Whatman 903 specimen collection 
card, Whatman 3MM chromatography paper, Whatman ion exchange chromatography paper and 
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Whatman glass microfiber filter paper [19]. Interestingly, all of the materials were commonly 
contaminated with palmitate (C 16:0) and stearate (C 18:0). Due to the incorporation of these FA 
contaminants during the methylation step in DBS analysis, their concentrations should be 
determined to see if their abundance is high enough to skew FA profiles of DBS samples in 
common dried blood spotting materials.  
The simple blood collection procedure for DBS enables larger field or clinical studies.  
This leads to challenges with sample processing as larger sample sets require greater storage 
and/or transportation capacities. Recently, the stability of PUFA during sample storage has been 
reviewed [32]. In brief, PUFA stability can between 0 and 8 weeks at ambient temperatures, 
between 21 and 90 days at 4C, and approximately 2 weeks at -20C [15, 36-39]. Metherel et al. 
showed that EPA + DHA levels had the largest decline at -20C in whole blood when compared 
to ambient, 4C and -75C temperatures [20]. The mechanism for this accelerated loss at -20C 
is not well understood but is thought to be attributed to the disruption of the erythrocyte structure 
with freezing and iron release, since -20C is not cold enough to prevent the oxidative process. 
Antioxidants have been used to prevent FA peroxidation as BHT-treated chromatography paper 
has been shown to reduce PUFA degradation in DBS samples and HUFA levels remains stable 
in for up to 21 days at ambient temperatures [15].  
 
2.4 Advances in Fatty Acid and Lipid Analyses  
The use of DBS samples for fatty acid analysis has increased based on advances in fatty 
acid and lipid analyses in the past 15 years [33]. These advances have increased analytical 
throughput, decreased costs and enabled larger sample sets to be analyzed.  DBS samples are 
 10 
well suited for high throughput initiatives as they are simple to collect but also have a reduced 
sample preparation time in comparison with the venous blood draw based sampling.  
Until recently, the limiting step in fatty acid analysis was the analysis of derivitized fatty 
acids by gas chromatography as individual sample run times could take over one hour.  The 
development of miniaturized capillary columns, improved temperature ramping and higher gas 
flow rates for gas chromatographs allowed for the development and adaptation of “fast” GC 
protocols.  GC run times for a FA profile can now be completed in as little as 10 min [40], which 
shifted the limiting analytical step towards cumbersome and tedious sample preparations [33].  
Traditionally, samples were prepared for fatty acid analysis by extracting the all lipids from the 
samples, saponifying the complex lipid to release the fatty acyls, and then derivitizing the free 
fatty acids to methyl esters [33].  These multiple steps are not amenable to automation and 
robotic handling, therefore the development of one-step chemical reactions [41] was the next 
critical step in increasing analytical throughput.  This also resulted in examining the blood 
collection process and the use of microwave energy to drive chemical reactions for additional 
throughput gains [7].   
It became clear that fingertip blood sampling and collection of DBS had significant 
throughput advantages [42, 43]. Because DBS samples are “dry” and there is no water in the 
sample to interfere with the chemical reactions, DBS samples can be directly transesterified to 
fatty acid methyl esters (FAMEs) without a lipid extraction step [7]. Samples containing 
considerable amounts of water typically require lipid extraction to get lipids in anhydrous 
organic solvents as water can interfere with the rapid boron trifluoride (BF3) catalyzed reaction 
(14%) in methanol [44].  The presence of water would result in the production of free fatty acids 
rather than the methanol being used to derivitize the fatty acyls to methyl esters. Making FAMEs 
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is required to optimize the resolution of each fatty acid peak by gas chromatography with flame 
ionization detection [45].  This resolution allows for consistent linear responses across all the 
individual fatty acids which provides simplified quantitation. 
One challenge with GC analysis is that the chemical derivatization required to produce 
FAMEs results in the loss of information about the native acyl species of complex lipids. While 
some of this information can be recovered by using additional techniques such as thin layer 
chromatography to isolate specific lipid classes prior to fatty acid determinations, the actual 
combinations of fatty acids on the lipids is never precisely known.  Advancements in mass 
spectrometry (MS) and the emergence of the field of lipidomics has resulted in the ability to 
determine and measure lipids in their native occurring state, including detailed information about 
their fatty acyl species [46]. MS based analyses can therefore provide more insights on acyl lipid 
species remodeling events and biological activities that are difficult to observe using GC based FA 
analysis.  This can be very useful for examining lipid metabolism during dietary intervention, 
pregnancy and metabolic diseases and can potentially reveal novel lipid blood biomarkers for 
dietary assessment and disease risk. However, at this time MS analysis remains costly, can be time 
consuming and the identification and quantitation of numerous lipid species remains problematic 
and difficult.  
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Chapter 3 
Rationale, Objectives and Hypotheses 
3.1 Rationale 
A drop of blood collected by a lancet from a FTP can be done quickly, is relatively 
simple to perform and requires little infrastructure when compared with venous blood draws.  
The simplicity and the lower cost per sample collected supports both field research and large 
clinical studies which can produce a large number of samples that require storage prior to 
shipment to an analytical facility.  FTP procedures typically result in the collection of unknown 
volumes of blood as DBS which prevents the ability to quantitate FA concentrations and limits 
data to qualitative units that can be less informative.  In addition, the materials used to collect 
DBS samples can be contaminated with lipids and fatty acids during manufacturing and/or post 
production handling.  Given that DBS samples are a comprehensive mixture of blood fractions 
and lipid pools, quantitative fatty acid data could be important to control for variability in 
samples due to conditions that could cause hypo- or hyper-lipidemia [47-49]. This thesis, 
therefore aims to address limitations in the ability to quantitate FA in DBS samples in 903 PSC, 
an industry standard, and a novel Mitra Microsampling Device.  Methods to determine blood 
volume in a DBS sample, the determination and impact of FA contaminants on quantitation, and 
FA stability during different storage conditions will be examined. 
 
3.2 Objectives 
 This thesis involves addressing three limitations in DBS quantitation that include; 
determining sample blood volumes, assessing FA contaminants on spotting materials, and FA 
stability during storage (see flow diagram: Figure 1). The initial objective was to develop a method 
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to determine unknown blood volumes of DBS.  For the commonly used 903 PSC, the relationship 
between blood volume and the area of spotted blood was examined to develop an equation to allow 
blood volume to be calculated from a hole punch of a defined area. An alternative solution involved 
the validation of the Mitra Microsampling Device, which collects 10 µL of blood, for FA analysis. 
The use of Mitra for a lipidomics analyses was also assessed using UHPLC-MS/MS and compared 
to a wet blood control. Fatty acid contaminants present on commonly used dried spotting materials 
was examined using blank 903 PSC and the Mitra devices by GC-FID and by UHPLC-MS/MS. 
Finally, the stability of FA in DBS stored on 903 PSC and the Mitra with and without antioxidants 
were tested under ambient, 4C, -20C and -80C conditions to determine fatty acid stability over 
3 months .  
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3.3 Hypotheses 
1. The area blood spotted on 903 PSC will have a strong positive linear correlation (r > 0.8) 
to the volume of blood applied. 
2. The linear relationship between area of blood and volume of blood will allow a 6mm hole 
punch to determine an unknown volume of blood from 903 PSC. The calculated volume 
will be used to determine FA concentrations through GC-FID which will yield similar FA 
profiles compared to pipetted wet blood controls. 
3. The Mitra Microsampling Device, a novel DBS device that wicks 10uL of blood will 
provide FA concentrations comparable with wet blood controls through GC-FID analysis. 
4. HPLC-MS will be used to determine fatty acyl species of complex lipids on DBS using 
lipidomic approaches and will be comparable to results from wet blood controls. 
5. GC-FID will identify palmitate and stearate fatty acids as contaminants on blank 903 PSC, 
Mitra tips and Whatman chromatography paper. HPLC-MS will identify palmitic and 
stearic free fatty acids on all materials.  
6. The HUFA status of DBS samples will decrease equally in all storage conditions (ambient, 
4C, -20C and -80C) in both the Mitra and 903 PSC. 
7. There will be an inverse relationship between temperature of storage and stability of 
HUFAs where decreasing storage temperatures will increase HUFA stability in DBS and -
20C which will show accelerated losses. 
8. The addition of BHT will increase the stability of HUFA in the DBS samples in both 
materials at all conditions, except at -80C which will show the most FA stability regardless 
of the presence of BHT. 
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Figure 1. Flow diagram addressing the main experiments in this thesis. The development of an 
equation to determine unknown amounts of blood on 903 PSC; using the equation to determine 
volume based on 6mm punch of 903 PSC; Mitra FA analysis validation; Mitra lipidomics 
validation; blank material FA contaminant identification through GC and UHPLC-MS/MS on 
903 PSC, Mitra and Whatman chromatography paper; storage experiment to determine FA 
stability using the 903 PSC and Mitra. 
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Chapter 4 
Common Methods 
 
Many of the methods in the present thesis were used for different objectives. In this chapter, 
the common methods are described in detail and can serve as a reference for the individual research 
chapters. All protocols and procedures have received approval from the Human Research Ethics 
Committee of the University of Waterloo. 
 
4.1 Blood Collection 
Venous blood was collected from the antecubital vein by a phlebotomist into sterile 
vacutainers to which 100 μL of 0.2M ethylenediaminetetaacetic acid (EDTA, Sigma-Aldrich) was 
added. Blood was aliquoted into smaller vials for application to dried spotting materials and 
storage. All DBS samples were allowed to dry at ambient temperatures and then stored at -75°C 
until analysis unless otherwise described.   
 
4.2 Lipid Extraction 
Total lipids were extracted from the DBS by adding 2:1 chloroform:methanol (v/v) and 
leaving at ambient temperatures for 24 hours [46]. Samples were then vortexed for 1 minute and 
500 μL of a 0.2M sodium phosphate buffer was added to induce separation of the aqueous and 
organic layers. Samples were inverted once and then centrifuged at 3000 rpm. The organic 
chloroform layer then collected and stored at 4ºC until further analysis.  
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4.3 Direct Methlyation and Methylation of Lipid Extracts 
Blood samples, or lipid extracts dried under nitrogen were combined with 300 μL of hexane 
containing a docosatrienoic acid (C22:3n-3) internal standard, and 1 mL of 14% boron trifluoride 
in methanol in a 5mL test tube with a silicon lined cap.   The samples were then heated for one 
hour at 100C on a block heater. Samples were removed and 1 mL each of hexane and water were 
added to the test tube followed by vortexing for 1 min and centrifugation at 3000 rpm for 5 minutes. 
The top layer containing the fatty acid methyl esters in hexane was removed, dried under nitrogen, 
and then reconstituted with 50 μL of heptane.  The fatty acid methyl esters were then transferred 
to GC vials for analysis by gas chromatography.  
 
4.4 Gas Chromatography – Flame Ionization Detection (GC-FID) 
GC-FID is the most commonly used technology for fatty acid analysis [33]. FAMEs were 
analyzed on a Varian 3900 gas chromatograph equipped with a nitroterephathalic acid modified 
polyethylene glycol capillary column with 15 m x 0.10 mm i.d. x 0.10 um film thickness and 
hydrogen as a carrier gas [20]. Volumes of 1 µL were introduced by a Varian CP-8400 autosampler 
with a split ratio of 200:1 into an injector heated to 250°C. The initial temperature was held for 
0.25min at 150°C followed by a 35°C/min ramp to 200°C, an incline of 8°C/min ramp to 225°C 
with a hold for 3.2 minutes to a final 80°C/min ramp up to 245°C for a 15-minute hold. The FID 
was set to 300°C with a nitrogen flow rate of 300mL/min.   
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4.5 Ultra-High Performance Liquid Chromatography with Tandem Mass Spectrometry 
(UHPLC-MS/MS) 
A Thermo Q-Exactive coupled with a Dionex UHPLC system was used to perform 
UHPLC-MS/MS experiments. Samples were resuspended in a solution of 65:30:5 
acetonitrile:isopropanol:water (v/v/v) with 0.1% formic acid. A C18 Ascentis Express column was 
used (15cm x 2.1mm x 2.0 um) with a binary solvent system. The two solutions for the mobile 
phase were; 60:40 acetonitrile:water (v/v), 10 mM ammonium formate and 0.1% formic acid (A) 
and 90:10 isopropanol:acetonitrile (v/v), 10 m M ammonium formate and 0.1% formic acid (B). 
The multistep gradient consisted of a mixture of the second solvent (B) into the first solvent (A) 
starting with a 32% ratio ramping up to 95% in 45 minutes [46]. Data was analyzed on the 
MassLynx 4.0 software. The tandem mass spectrometry (MS/MS) spectra was exported to the 
NIST 2.0 program for lipid identification using the LipidBlast database.  
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Chapter 5 
Development of a Quantitative Method to Determine Fatty Acid 
Concentrations on 903 Protein Saver Cards and Validating the Mitra 
Microsampling Device for Fatty Acid Analysis 
 
5.1 Introduction  
 The fatty acid profiling of DBS samples is increasing due to advantages in simplified 
sample collection, handling and processing.  However, DBS collection has limitations because 
volume of blood collected on a paper matrix is usually unknown. As a result, FAs cannot be 
expressed as concentrations and must be represented percent of the total FA (%TFA). Most of 
the available literature using DBS sampling procedures express their FA data as relative 
percentage [4] due to the unknown volumes, unless blood is previously quantitated.  
 In this chapter, the relationship between blood volume pipetted and blood spot area on 
903 PSC will be determined. This relationship will then be used to calculate the volume of blood 
on a 6mm punch of DBS on a 903 PSC. The Mitra Microsampling Device (Figure 1) that is 
designed to wick 10 μL of blood will also be validated for quantitative FA analysis. This device 
is designed to wick an accurate volume of blood regardless of hematocrit level and has been used 
for other analytes including cancer metabolomics and steroids determinations [50, 51] but not 
fatty acids and lipidomics. 
  
5.2 Methods 
In the first study, whole blood was collected by venipuncture with EDTA from one fasted 
healthy male participant as described above in Chapter 4.  Five different volumes (15, 20, 25, 30 
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and 35 μL) were pipetted in triplicate onto 903 PSC (Sigma Aldrich, Oakville, CAN) and left to 
dry at ambient temperatures.  Images were taken by 12 MP camera on a Samsung S7 Edge and 
saved as jpg files. Image were then analyzed using ImageJ software to determine accurate areas 
for each blood spot.  The mean DBS area and known blood volumes were plotted and the linear 
equation was determined and assessed by a correlation coefficient.  
In the second study, venous whole blood was taken from ten healthy adults attending the 
University of Waterloo that fasted overnight.  Samples were aliquoted as wet whole blood (35 
μL), DBS on 903 PSC and DBS on the Mitra (Neoteryx, Torrance, CA). For the 903 PSC, 
approximately 35 μL was applied, allowed to dry and then a Harris Uni-Core punch (Sigma 
Aldrich, Oakville, CAN) was used to remove a 6mm hole from the center of each spot, which 
was transferred to a test tube. For collection on the Mitra, the device was held at the surface of 
blood at 45 until completely saturated and left to dry at ambient temperatures for an hour. The 
Mitra tip was then removed and placed in a test tube.  Direct transesterification was used to 
derivitize the fatty acyls and acids to methyl esters (Chapter 4, Section 4.3). In summary, final 
blood volumes that were used were 35 μL for wet blood, 9.6 μL for 903 PSC (see below for 
calculations) and 10 μL for the Mitra.   The FAMEs were then analyzed by GC (Chapter 4, 
Section 4.4).  
The fatty acid compositions of the wet blood and DBS were expressed as concentrations 
and relative percentages and compared by one-way ANOVA with Tukey’s post hoc testing to 
determine differences between individual means.  Bland-Altman plots were also used to examine 
the concordance between wet blood and the DBS collection materials.  This was completed for 
the sum of the concentrations of EPA and DHA and the % of n-3 HUFA in total HUFA as these 
biomarkers of n-3 LCPUFA status are commonly used in the literature.      
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5.3 Results 
 In study 1, the area of each blood spot was proportional to the volume of blood applied 
(Figure 2).  After calculating the areas with Image J and plotting against the blood volumes 
(Figure 3), a linear relationship was determined (y = 0.029x, r = 0.99, P < 0.001). This equation 
was applied to the 6mm hole punched from the DBS on 903 PSC indicating that the hole punch 
contained 9.6 μL of blood.   
 In study 2, the mean fatty acid profiles for the ten individuals using the three different 
collection methods were relatively similar.  Concentration values (μg FA/ mL blood) did not 
show any significant differences for the sums of saturated fatty acids (SFA), monounsaturated 
fatty acids (MUFA), n-6 an n-3 polyunsaturated fatty acids (PUFA), highly unsaturated fatty 
acids (HUFA), and total fatty acids concentrations (Figure 4).  In addition, there were no 
differences between commonly used biomarkers of omega-3 status (EPA+DHA, N-6/N-3, 
HUFA score) (Figure 5).  However, there were significant differences for a few individual fatty 
acids (Table 1).  These included significantly higher recoveries of C 10:0, C 12:0,  C 12:1 and C 
22:1n-9 and lower recoveries of C 22:0 for the Mitra and solely higher recoveries of C 22:0 for 
the 903 PSC in comparison to wet blood controls. When the fatty acids were expressed as 
relative %, there were no significant differences between any of the individual fatty acids, sums 
of fatty acid and/or ratios or biomarkers (data not shown).  This was explored further by 
presenting the ranges of classes of fatty acids (Table 2).  Within a sample set of 10 heathy 
individuals, the ranges were much wider when the data was expressed as concentrations. 
Concordance analysis between wet whole blood and DBS collection materials for EPA + DHA 
and the % of n-3 HUFA in total HUFA by Bland-Altman plots indicated the 95% confidence 
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intervals of the bias (average difference between whole blood and spotting method) extended 
beyond zero.   
  
5.4 Discussion 
Based on our results, it appears that DBS collected by 903 PSC and Mitra can be used for 
accurate fatty acid profiling. The blood volume and blood area on 903 PSC showed a strong 
linear correlation (r = 0.99, P < 0.001) that allowed for the determination of blood volumes when 
fatty acid profiles from 903 PSC, Mitra and wet blood were compared. There were some 
statistical differences between some individual fatty acids, specifically C 10:0 and C 12:0, but 
these were very low abundant fatty acids (each was < 0.5% of total fatty acids) with little impact 
to fatty acid subgroups.  Concordance testing indicated that both the 903 PSC and Mitra are 
capable of providing omega-3 status results similar to wet blood analysis. To our knowledge, this 
is the first report of fatty acid concentrations in DBS.  Previous studies reporting DBS fatty acids 
have presented the relative % of total fatty acids [7, 11, 13, 20, 42, 52].  Blood volume estimates 
of DBS hole punches have been shown to be linear to blood area on 903 PSC previously for 
other metabolites (REF 5).  For fatty acid analyses, a 6mm DBS punch  has been shown to have 
an average blood volume of 8.7 ± 1.9 µL on PUFAcoat cards, however this material in thinner 
and less absorbant due to silica gel coating [53].   The 903 PSC and Mitra examined in this 
chapter have shown to provide similar results to wet blood controls using technical replicates and 
blood from healthy participants. These preliminary results indicate that quantitative fatty acid 
determinations are possible from DBS. Further validation should be completed on different 
populations such as children, aging populations and malnourished individuals, which may have 
high or low hematocrit.  
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These observations have limitations.  The assessment was completed using technical 
replicates, therefore the impact of biological variation was not assessed directly. Biological 
variation was indirectly assessed when the 9.6 μL volume for a 6mm punch was applied to the 
903 PSC DBS samples collected from the 10 individuals and compared to wet blood and the 
Mitra. However, the study sample was restricted to a healthy young population sample that 
fasted prior to blood sampling. Given field studies often target different populations such as 
children, the elderly or malnourished, and that postprandial conditions can vary, additional 
research is needed to validate these DBS collection materials under different conditions.  The 
variability in DBS area to blood volumes is related to blood viscosity that is determined by 
hematocrit levels, plasma viscosity, and erythrocyte aggregation and deformation.  This could 
result in different linear equations to define the DBS area and blood volume relationship on the 
903 PSC. However, using a small area/low volume of blood as we did, should minimize the 
effects of variation in DBS dispersion. There is evidence in the literature, that a “volcano” effect 
can occur with blood dispersion where the volume of blood per unit area is decreased around the 
edges of the DBS. Therefore, removing a hole punch towards the center of the DBS should 
provide an accurate unit of volume per unit of area. 
 
5.5 Conclusions 
 In conclusion, quantitative FA profiling of DBS from healthy individuals is possible. This 
can be done by characterizing the blood volume/DBS area dispersion of the 903 PSC or by 
collecting a known volume of blood using a novel Mitra collection device.  Further method 
validation is required with a larger sample size and especially in populations that may have 
different DBS blood dispersion on collection materials.  
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Figure 2. Mitra Microsampling Device (10 μL) with and without blood [54]. 
 
 
 
 
 
 
 
 
Figure 3. Whole blood spotted on 903 Protein Saver Cards. Volumes of 35, 30, 25, 20 and 15 μL 
were pipetted into the center of each spot and areas were determined using ImageJ. 
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Figure 4. Linear relationship between volume of blood pipetted and saturated are on 903 Protein 
Saver Cards. The resultant equation was y = 0.029x where the y variable is the area in cm2 and 
the x variable is volume in μL.  Linear regression and p- values were determined, n = 3 for each 
volume point.  
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Figure 5. Concentrations (μg FA/ mL of blood) of fatty acid groups in whole blood, 903 Protein 
Saver Cards and Mitra. SFA, saturated fatty acids; MUFA, monounsaturated fatty acid. Each bar 
represents means with error bars representing the S.D., n = 10.  
 
 
Figure 6. Concentrations (μg FA/ mL of blood) of biomarker status in whole blood, 903 Protein 
Saver Cards and Mitra. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DPA, 
docosapentaenoic acid; PUFA, polyunsaturated fatty acid; HUFA, highly unsaturated fatty acid; 
n-6, omega-6; n-3, omega-3. Each bar represents means with error bars representing the S.D., n = 
10.   
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Table 1 FA compositions of wet blood control, 6mm hole punched 903 PSC and Mitra (μg FA/ 
mL of blood)      
 
 
Asterisk used to highlight significantly different values (in comparison to wet blood control) 
after one-way ANOVA + Tukey HSD post-hoc test with p < 0.05. Data shown as mean ± SD. 
  
Fatty Acid   Whole Blood Dried Blood Spot Mitra Microsampler 
C 10:0 0.1 ± 0.1 0.1 ± 0.1 0.7 ± 0.3* 
C 12:0 0.3 ± 0.1 0.5 ± 0.3 0.9 ± 0.3* 
C 14:0 2.0 ± 1.0 2.4 ± 0.9 3.3 ± 1.0 
C 16:0 58.5 ± 13.6 60.1 ± 13.3 65.3 ± 13.2 
C 18:0 32.4 ± 7.5 31.8 ± 3.2 36.4 ± 3.5 
C 20:0 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 
C 22:0 3.1 ± 0.4 3.7 ± 0.3* 2.5 ± 0.3* 
C 23:0 0.7 ± 0.1 0.8 ± 0.2 0.6 ± 0.1 
C 24:0 5.9 ± 0.8 5.3 ± 1.1 4.8 ± 0.7 
C 12:1 0.1 ± 0.1 0.1 ± 0.1 1.0 ± 0.9* 
C 14:1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 
C 16:1 2.6 ± 2.0 2.8 ± 1.9 3.1 ± 2.0 
C 18:1n-7 4.3 ± 1.0 4.8 ± 1.0 5.0 ± 1.1 
C 18:1n-9 44.2 ± 11.2 50.2 ± 9.3 52.4 ± 11.4 
C 20:1n-9 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.1 
C 22:1n-9 0.2 ± 0.2 0.3 ± 0.2 1.7 ± 0.4* 
C 24:1n-9 6.6 ± 0.9 5.5 ± 1.1 5.3 ± 1.0 
C 18:2n-6 60.0 ± 9.5 64.5 ± 10.1 64.3 ± 9.9 
C 18:3n-6 0.7 ± 0.3 0.8 ± 0.3 0.7 ± 0.3 
C 20:2n-6 0.2 ± 0.2 0.4 ± 0.5 0.2 ± 0.2 
C 20:3n-6 4.0 ± 1.5 4.0 ± 1.4 4.1 ± 1.4 
C 20:4n-6 29.8 ± 5.9 29.4 ± 5.0 29.4 ± 5.4 
C 22:2n-6 0.1 ± 0.1 0.2 ± 0.2 0.1 ± 0.1 
C 22:4n-6 3.9 ± 0.9 3.7 ± 0.8 3.7 ± 0.8 
C 22:5n-6 1.2 ± 0.5 1.5 ± 0.8 2.2 ± 0.4 
C 18:3n-3 1.4 ± 0.6 1.6 ± 0.6 1.5 ± 0.6 
C 20:3n-3 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 
C 20:5n-3 1.5 ± 0.6 1.5 ± 0.5 1.8 ± 0.5 
C 22:5n-3 3.2 ± 0.3 3.3 ± 0.6 3.4 ± 0.6 
C 22:6n-3 7.7 ± 2.3 7.3 ± 2.1 7.4 ± 2.1 
C 20:3n-9 0.6 ± 0.3 0.7 ± 0.1 0.7 ± 0.1 
Total 276.9 ± 47.3 289.0 ± 43.3 304.1 ± 45.4 
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Table 2 FA ranges expressed as relative percentages (%TFA) and concentrations (μg FA/ mL 
of blood).  
FA Groups 
Relative Percent 
(%TFA) 
Concentration 
(μg FA/ mL of blood) 
SFAs 34.0-40.0 79.0-143.4 
MUFAs 17.7-24.5 40.6-88.2 
N-6 32.1-37.1 81.9-140.6 
N-3 3.9-5.4 9.7-21.1 
EPA+DHA 2.0-3.8 4.8-14.8 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acid, n-6, omega-6; n-3, omega-3; 
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PUFA, polyunsaturated fatty acid; 
HUFA, highly unsaturated fatty acid. Data is presented as range (min – max), n = 10. 
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Figure 7. Concordance testing of 903 PSC, Mitra and whole blood for EPA + DHA levels. A. 
903 PSC, B. Mitra. Sample tests completed on difference; whole blood, 903 PSC and whole 
blood, Mitra. (n = 10). 
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Figure 8. Concordance testing of 903 PSC, Mitra and whole blood n-3 HUFA in total HUFA. A. 
903 PSC, B. Mitra. Sample tests completed on difference; whole blood, 903 PSC and whole 
blood, Mitra. (n = 10). 
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Chapter 6 
Identification of Fatty Acid and Lipid Contaminants  
Commonly found in Blank Dried Blood Spotting Materials 
6.1 Introduction  
DBS collections use materials that may be contaminated with lipids. Using gas 
chromatography methods, lipids are either extracted or the fatty acyls on lipids are directly 
transesterified prior to fatty acid composition analysis. However, due to this procedure, any lipid 
and fatty acid contaminants on the DBS collection materials can be incorporated into the biological 
sample which potentially reduces the accuracy and precision of the FA determinations.  
In the past, measures have been taken to reduce the prevalence of contaminants by soaking 
the materials in a methylating agent for 1h, 3h and 10h at ambient temperatures and 1h, 2h and 3h 
at 70°C. The study showed a 60% reduction in contaminants after 2h and 80% reduction after 3h 
at 70°C but the texture of the cards was destroyed and unusable [19]. Alternatively, others have 
used a 2:1 choloroform:methanol wash (v/v) to remove nearly 80% of the contaminants for most 
collection papers in 3h [19]. Although methods exist to treat collection materials to remove 
contaminants, certain materials with cosmetic features such as ink cannot be washed. Saturated 
FA, specifically palmitate (C 16:0) and stearate (C 18:0) are the commonly found contaminants 
on tested dried spotting materials [19].  
Understanding the concentration and type of contamination in commonly used spotting 
materials can be used to see how FA profiles in biological samples may be affected. The 
experiments in this chapter will examine contaminants on 903 Protein Saver Cards, Whatman 
chromatography paper and the Mitra through GC analysis. These three materials were chosen due 
to the popularity in 903 PSC in FA literature, the prevalence of Whatman chromatography strips 
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in our current lab use and no information on the current blank FA profile on the Mitra. UHPLC-
MS/MS will also be used to determine the actual lipid source of the fatty acid contaminants. 
6.2 Methods 
Blank Whatman chromatograph paper, 903 PSC and Mitra tips without blood samples were 
used and all materials were handled using nitrile gloves.  In triplicate, hole punches (6mm) were 
taken from the paper materials, and tips were removed from the Mitra, and then placed in clean 
glass test tubes.  Total lipids were extracted from tips using a modified Folch protocol [55]. In 
brief, the samples were submerged in 3 mL of 2:1 chloroform:methanol (v/v) and incubated 
overnight. The organic chloroform layer was then separated using a sodium phosphate buffer 
(Na2PO4) and separated into two aliquots. 
The first aliquot was used in study 1 for GC analysis. The organic chloroform layer was 
dried under nitrogen and FAMEs were prepared using 14% boron trifluoride in methanol. The 
FAMEs were then analyzed by GC as described in Chapter 4 (4.3, 4.4). 
 The second aliquot of chloroform was used in study 2 for mass spectrometry analysis. The 
sample was dried under nitrogen and then re-suspended in 65:35:5 acetonitrile:isopropanol:water 
+ 0.1% formic acid and analyzed using a reverse phase UHPLC multi-step binary protocol as 
described in section 4.5. Positive ESI mode was used to identify all lipid species but could not 
identify FFA species. Therefore, negative ESI mode was used to detect FFA because of the 
chemical properties of the compound, specifically the deprotonated form of the carboxylic acid 
(R-COO-). A spray voltage of -3.0kV was used to ionize and identify the FFA species. The mass 
spectra was exported to the NIST 2.0 program for lipid identification using the LipidBlast 
database.  
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6.3 Results 
In the first study, 16:0 and stearic 18:0 fatty acids were identified in all three DBS 
collection materials through GC-FID analysis and no other fatty acids were detected. Specifically, 
Whatman chromatography paper had the highest level of contaminants with 0.97±0.08 μg of 16:0 
and 1.43±0.16 μg of 18:0 per 6mm punch, the 903 PSC had 0.64±0.05 μg of 16:0 and 0.88±0.04 
18:0 per 6mm punch and the Mitra had 0.80±0.08 μg 16:0 and 0.98±0.10 μg 18:0 per tip.  
The second study used the GC results for the UHPLC-MS/MS analysis to perform a 
targeted search for lipids containing stearate and palmitate. Negative ionization mode identified 
palmitic acid and stearic acids in all materials as free fatty acids with the [M-H]- mass-to-charge 
ratios of 255.23 and 283.26 respectively. Additionally, positive mode analysis revealed that the 
Mitra tips also contained palmitoyl and stearoyl lysophosphatidylcholines (LysoPC) with [M+H]+ 
m/z ratios of 496.34 and 524.37, respectively.  
6.4 Discussion 
This study suggests that Whatman chromatography paper, 903 PSC and the Mitra are all 
contaminated with palmitate and stearate containing lipids. The presence of these contaminants 
can skew FA profiles due to the inclusive methylation protocol through GC-FID analysis. Pre-
treatment of chromatography papers can be used to reduce concentration amounts on certain 
collection materials. However, FA species and abundances should be determined in circumstances 
where washing procedures cannot be applied. Whatman chromatography paper showed the highest 
amount of C 16:0 and C 18:0 contaminants followed by Mitra and then 903 PSC. The amount of 
contaminants when compared to C 16:0 and C 18:0 in the blood of the healthy subjects is 
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minuscule and well below the typical variation observed with intra-individual analysis. Given the 
prevalence of FA contaminants is below 1 μg, it does not impact the total concentrations by much, 
as we estimate the contaminants are 1% of the total C 16:0 and 3% of C 18:0 in blood. 
Contaminants including C 20:0 and C 22:0 have been identified on 903 PSC previously, but at 
extremely concentrations [19]. We did not detect C 20:0 and C 22:0 by either GC-FID or UHPLC-
MS.  We analyzed blank 6mm (0.28cm2) punches of 903PSC with minimal handling.  The previous 
study examined a 1.5 X 1.5 cm blank (2.25cm2) that was treated with an internal standard [19].  
Therefore, the C 20:0 and C 22:0 could have been below the limits of detection for our analyses, 
or they were introduced onto the blanks during handling in the previous study.  Further testing 
should be completed on glassware, solvents and plastics (such as pipette tips) and different steps 
of sample processing during FA analysis to identify potential sources of contamination. 
The fact that the Mitra was the only material to have palmitoyl and stearoyl 
lysophosphatidylcholines was interesting. While lysophosphatidylcholines exist naturally in 
various sources, their presence in the absence of phosphatidylcholines suggests they have been 
added to the material intentionally.  Lysophosphatidylcholines or lysolecithin has industrial 
applications as wetting and/or emulsification agents [56].  Therefore, the lysoPC could be 
intentionally added to contribute to the wicking abilities of the Mitra because of its water soluble 
and fat soluble properties (also seen in emulsifiers). If lipidomics analysis is used, these lysoPC 
species can be selectively excluded as contaminants from the data extraction or acquisition and 
the remaining complex lipids can still be characterized fully.   
 This study shows that FA contaminant exist, but that they have low impact on blood FA 
profiles in DBS. Steps can be taken to “wash” materials to remove the SFA contaminants; 
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however, this can effect ink on the 903PSC and potentially impact the wicking capabilities of the 
Mitra.   
 
6.5 Conclusions, Limitations and Future Directions 
 In conclusion, palmitate and stearate FAs were found on Whatman chromatography paper, 
903 PSC and the Mitra. The m/z ratios of these FAs were used to identify their encompassing 
lipids using mass spectrometry. Palmitic and stearic FFAs were identified in all materials and 
palmitoyl and stearoyl LysoPCs were identified solely in the Mitra. A more comprehensive 
determination of contaminants should be completed by examining different batches of each 
material to test the consistency of the contaminants present. 
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Chapter 7 
Lipidomic Profiling of Human Whole Blood using the 10 L Mitra 
Microsampling Device 
7.1 Introduction  
Blood fatty acid profiling has shown a link between lipid metabolism, dietary intake and disease 
risk. FA analysis is commonly gas chromatography based and require a derivatization reaction to 
prepare FAMEs for analysis and as a result, there is no available information on the fatty acyl 
parent lipid species. Techniques such as thin-layer chromatography (TLC) can isolate lipid 
classes before FAs are determined but the acyl species of the original lipids remain unknown 
[57]. The advances in UHPLC-MS/MS has enabled the identification of complex lipid species as 
they exist in biological samples. A recent study has determined lipidomic profiles on Whatman 
cellulose paper, the first of its kind to apply lipidomics to DBS samples [46]. The development 
of a high-throughput UHPLC-MS/MS method identified a vast number of lipid species that 
occurred in DBS samples and also addressed the complexity in studying whole blood lipids due 
to the polar and non-polar lipid mixtures and range of abundances as well as the retention of 
specific lipids on the collection materials. The untargeted lipidomics profiling method 
characterized the main lipid species in blood including phosphatidylserine (PS), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylcholine (PC), 
triacylglycerol (TAG) and cholesterol esters (CE). The other two recorded studies on DBS 
lipidomics used Ahlstrom 226 collection cards to determine lipid species in infant heel prick 
collections [58, 59]. This chapter examines the ability to use the Mitra sampling device for 
lipidomic assessments of DBS. A semi-quantitative, untargeted UHPLC-MS/MS method is used 
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and the lipid species identified in the Mitra was compared to those identified in wet blood 
controls.  
7.2 Methods 
Whole blood was collected by venipuncture with EDTA from one fasted healthy male 
participant as described above in Chapter 4 (Section 4.1). Samples were aliquoted as wet whole 
blood (35 μL) into clean test tubes and the Mitra tips were held at 45 until completely saturated, 
left to dry at ambient temperatures and placed into clean test tubes. Total lipids were extracted 
from tips using a modified Folch protocol [55]. In brief, the samples were submerged in 3 mL of 
2:1 chloroform:methanol (v/v) and incubated overnight. The organic chloroform layer was then 
separated using the lipid extraction protocol discussed in Section 4.2 dried under nitrogen. Samples 
were then re-suspended in 65:35:5 acetonitrile:isopropanol:water + 0.1% formic acid and analyzed 
using a reverse phase UHPLC multi-step binary protocol as described in section 4.5. The lipids 
were presented as arbitrary units which is the qualitative ratio between amount of substance 
compared to a predetermined reference measurement, in this case a 17:0/17:0 PC internal standard 
(Avanti, Alabaser, AL). The mass spectra were exported to the NIST 2.0 program for lipid 
identification using the LipidBlast database. 
7.3 Results 
There were significant differences between the lipidomics profiles generated from the 
Mitra DBS and the wet whole blood control. The Mitra DBS resulted in significantly lower 
amounts of 16:0/18:2 PC, 16:0/20:4 PC, 18:0/22:6 PS, 16:0 lyso PC and 18:0/20:4 PS.  
However, a pattern in the other PC species that were not significantly different was also observed 
in that all the PC compounds where roughly 10% lower when determined from Mitra DBS.  For 
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PE, 16:0/18:2 PE was also roughly 10% lower (not significantly different) but 16:0/22:6 PE from 
Mitra was very similar.  Determinations of PS species were particularly low from the Mitra 
(approximately 55% lower than control) as well as 16:0 lysoPC (32% lower than control). In 
contrast, the Mitra lipidomics profile showed consistent higher but not significant recoveries of 
the identified TAG (10-15% higher) and CE (29% higher) species; 16:0/18:1/18:2 TAG, 
16:0/18:1/18:1 TAG, 18:1/18:1/18:2 TAG and 18:2 CE (Table 3).  
7.4 Discussion 
The generally lower recoveries of phospholipids (~10%) and higher recoveries of 
TAG/CE species is likely due to the polarity of the compounds and interactions with the Mitra 
tip and the ability to extract lipids from the Mitra tip.  A recent study examining extraction 
protocols for lipidomics from DBS on chromatography paper showed similar profiles to wet 
blood could be obtained with 24h exposure to extraction solvents, homogenization of the 
collection material, and acid treatment to assist in recovering PS species [46]. The PS recovery 
required acid extraction to disrupt the hydrogen bonding between the carboxylic acid group of 
PS with the cellulose fibers in the paper [46].     
While the Mitra tip composition is proprietary, it appears to share some of the properties 
of chromatography paper in regard to the retention of lipids.  The three dimensional shape (cone) 
of the Mitra appears to result in less contact exposure to the extraction solvents 
(chloroform:methanol, v/v) during the overnight soak in compared with the relatively two 
dimensional shape of  DBS on chromatography paper resulting in potentially poorer extraction 
efficiencies.  The decreased extraction efficiencies of the polar lipids presently observed strongly 
suggests that the Mitra tips are made of a polar material that is retaining polar compounds, 
particularly acidic compounds The higher recoveries of TAG/CE species we observed with the 
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Mitra tip suggests extraction efficiencies for non-polar compounds are relatively high, and is 
further evidence that the Mitra materials are nonpolar.  The slightly higher recoveries of the 
nonpolar lipids from the Mitra tip relative to whole blood is likely due to the use of a polar lipid 
internal standard (17:0/17:0 PC) to calibrate responses in the mass spectrometer.  Lower 
recoveries of the internal standard likely resulted in an overestimation in the amounts of the polar 
lipids.    
7.5 Conclusions, Limitations and Future Directions 
In conclusion, the Mitra was not validated for semi-quantitative lipidomics assessment. 
However, it appears that additional steps in the extraction of the lipids from the Mitra could 
enable validation in the future.  Understanding the materials and specific chemical composition 
of the Mitra tip would facilitate validation but at this time this information remains unknown.  It 
would appear that many of the steps defined by Henao et al. [46] could be applied to improve 
lipidomic profiling from DBS collected by Mitra tips.  
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Table 3 Lipidomic examination of the Mitra and a wet blood control 
 
Lipid Ion m/z Mitra Mean WB Mean % of WB 
16:0/18:2 PC* [M+H]+ 758.57 10.6 ± 0.80 12.1 ± 0.24 88 
16:0/20:4 PC* [M+H]+ 782.57 7.94 ± 0.16 8.46 ± 0.27 94 
16:0/18:1 PC [M+H]+ 760.59 3.66 ± 0.27 3.98 ± 0.11 92 
18:0/18:2 PC [M+H]+ 786.6 3.27 ± 0.16 3.54 ± 0.08 92 
16:0/18:1/18:2 TAG [M+NH4]+ 874.79 3.42 ± 0.28 3.11 ± 0.11 110 
16:0/18:1/18:1 TAG [M+NH4]+ 876.81 3.20 ± 0.26 2.79 ± 0.10 115 
18:2 CE [M+NH4]+ 666.62 1.32 ± 0.32 1.03 ± 0.03 129 
18:1/18:1/18:2 TAG [M+NH4]+ 900.81 1.09 ± 0.08 0.98 ± 0.03 111 
18:0/20:4 PC [M+H]+ 810.6 0.91 ± 0.05 1.01 ± 0.05 90 
18:0/18:1 PC [M+H]+ 788.62 0.82 ± 0.06 0.90 ± 0.02 91 
16:0/22:6 PC [M+H]+ 806.57 0.78 ± 0.04 0.85 ± 0.02 91 
18:0/22:6 PS* [M+H]+ 836.54 0.43 ± 0.34 0.93 ± 0.03 46 
16:0 LPC* [M+H]+ 496.34 0.46 ± 0.20 0.67 ± 0.03 68 
16:0/22:6 PE [M+H]+ 764.52 0.58 ± 0.02 0.56 ± 0.01 103 
18:0/20:4 PS* [M+H]+ 812.54 0.27 ± 0.11 0.61 ± 0.03 45 
18:0/22:6 PC* [M+H]+ 834.6 0.21 ± 0.01 0.24 ± 0.01 91 
16:0/18:2 PE [M+H]+ 716.52 0.07 ± 0.01 0.08 ± 0.01 90 
Arbitrary units (AU), Mass-to-charge ratio (m/z); Phosphatidylcholine (PC); 
Phosphatidylethanolamine (PE); Phosphatidylserine (PS); Triacylglycerol (TAG); Cholesteryl 
ester (CE); Highly unsaturated fatty acid (HUFA). Asterisk used to highlight significantly 
different values after one-way ANOVA + Tukey HSD post-hoc test with p < 0.05. (n = 5). 
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Chapter 8 
Fatty Acid Changes in Dried Blood Spots when Stored at Various 
Temperatures 
8.1 Introduction  
 The proper storage and transport of biological samples are integral to maintain FA 
stability in DBS. Field studies with limited access to ultra-cold storage or analytical laboratories 
should consider their best option for storage and use anti-oxidants to preserve FA profiles. 
Currently, only a few studies have assessed the stability of FTP profiles stored on 
chromatography paper [7, 11, 14, 15, 20]. Findings have shown PUFA stability to be between 0 
and 8 weeks at ambient temperatures, between 21 and 90 days at 4C, two weeks at -20C and 
longer than 30 days at -40C [15, 37-39, 43].  Although -20C is often considered the second 
best storage option compared to -80C, Metherel et al. [14] showed that -20C storage has the 
highest instance of FA loss in comparison with 4C and ambient temperatures and its use should 
be avoided if possible. In addition to using ultra-cold storage conditions, the antioxidant 
butylated hydroxytoluene (BHT) has been shown to improve PUFA stability between 3 weeks 
and 3 months at 4C and less than 2 months at room temperature [15]. This study also showed 
that using a concentration of 5.0 mg/mL of BHT in blood can prevent HUFA degradation and 
EPA + DHA degradation from baseline for up to 28 days and PUFA degradation for up to 8 
weeks at ambient temperatures.  
Currently, there is there no literature on FA stability for the 903 PSC and Mitra for 
different storage conditions. Determining FA behavior can aid with the understanding of sample 
collection, transport and storage prior to analysis by clinical, medical and academic researchers. 
Blood from 10 participants were spotted onto 903 PSC and Mitra and stored at ambient, 4C, -
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20C and -80C temperatures and wet blood was stored at -80C to act as controls for each 
extraction point. The conclusions made from this chapter can be used to develop a deeper 
understanding of FA stability which can be used to guide academic, research, clinical and 
medical sample collection and storage.    
 
8.2 Methods 
Venous blood was collected from the antecubital vein into two vacutainers, one with 
BHT and one without BHT, for each of the ten fasted, healthy, adult participants as described in 
Chapter 4, Section 4.1. Samples were aliquoted as wet whole blood in a cryovial, DBS on 903 
PSC and DBS on the Mitra. For the 903 PSC, approximately 35 μL was applied to the center of 
each spot and allowed to dry at ambient temperatures. A Harris Uni-Core punch (Sigma Aldrich, 
Oakville, CAN) was used to remove a 6mm hole from the center of each spot and then 
transferred to a clean test tube. For blood collection on the Mitra, the device was held at the 
surface of blood at 45 until completely saturated (10 μL) and left to dry at ambient temperatures 
for an hour. The Mitra tip was then removed and placed in a test tube.  Samples were then stored 
at ambient, 4C, -20C and -80C conditions and lipids extracted at baseline, 1 week, 2 week, 4 
week, 8 week and 12 week time points. For wet 35 μL of blood was used for lipid extraction. 
FAMEs were prepared using 14% boron trifluoride in methanol and were analyzed through GC 
as described in Chapter 4, Section 4.3, 4.4. 
Individual fatty acids were identified by comparison to an external reference standard and 
data was expressed as the relative weight percentage of total fatty acids and as concentrations per 
volume of blood. Common biomarkers such as the relative percentage of EPA + DHA (omega-3 
index) and percentage of n-3 HUFA in total HUFA were also calculated.  The effect of storage 
 43 
temperatures, time, blood collection materials and anti-oxidant use on the percentage of 
EPA+DHA were assessed using a three-way ANOVA with repeated measures as it is the most 
popular biomarker, and it has been shown to be sensitive to oxidative losses [14].  In addition, 
repeated measure ANOVAs were used for each condition to examine the effect of time on the 
percentage and concentration of EPA + DHA, the percentage of n-3 HUFA in total HUFA and 
individual fatty acids.  After a significant F-value as determined for a repeated measures 
ANOVA, post hoc tests were performed using a Dunnett’s test with baseline data as control with 
statistical significance inferred when p < 0.05.  
 
8.3 Results 
The interaction between time  collection material  storage temperature  antioxidant 
use was not significant.  Time and storage temperature were involved in several significant 
interactions, while the use of antioxidant largely required interaction with time for a significant 
F-value.  Collection material tended to be involved in significant effects except for an interaction 
with time and antioxidant use.  To simplify, the relative percentage for EPA + DHA are 
presented according to the repeated measures ANOVA for each condition with post hoc 
comparisons to baseline levels (Table 4).  The 903 PSC without BHT had no differences for up 
to 8 weeks compared to baseline at ambient and 4C  storage conditions and significant losses as 
soon as 1 week at -20C. With BHT, there were similarly no significant differences from 4 to 8 
weeks at ambient and 4C however it did increase the stability of the ratio from 4 8 weeks at -
20C. The Mitra presented similar results to the 903 PSC. In brief, the Mitra without BHT had 
FA stability for 4 to 8 weeks at baseline and 4C, but was significantly lower as soon as 1 week 
at -20C. With the addition of BHT to the Mitra, the EPA + DHA ratio was still stable for 4 to 8 
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weeks at ambient and 4C and up to 2 weeks at -20C. Over the 12 week storage period, both the 
903 PSC and Mitra did not show any significant losses at -80C. 
The n-3 HUFA in total HUFA ratio was determined in relative abundance (%TFA) at all 
conditions for both the 903 PSC and the Mitra (Table 5). The 903 PSC without BHT did not 
show any significant differences from baseline for the n-3 HUFA in total HUFA ratio for up to 8 
weeks at both ambient and 4C storage conditions. The -20C condition showed significant 
differences as soon as week 2 without BHT but increased from 4 to 8 weeks with BHT. With the 
addition of BHT, the n-3 HUFA to total HUFA ratio was not significantly different from baseline 
for 4 to 8 weeks at ambient and 4C storage conditions. As expected, the -80C storage condition 
showed no significant differences from baseline for up to 12 weeks.  The Mitra without BHT 
showed similar results to the 903 PSC. Significant differences were observed from baseline at 8 
weeks with no BHT at ambient temperatures and 4C conditions and 2 week at -20C. The 
addition of BHT had no differences from baseline for 4 to 8 weeks at ambient, 4C and -20C. 
Similar to the 903 PSC, the -80C condition showed no significant differences from baseline for 
up to 12 weeks. 
To determine actual losses of EPA + DHA rather than relative changes, concentrations 
were determined in ambient, 4C, -20C and -80C conditions over 12 weeks for 903 PSC 
(Figure 8). From baseline at ambient and 4C temperatures, EPA + DHA concentrations were 
not significantly different for up to 8 weeks with and without the addition of BHT. At -20C, 
EPA + DHA concentrations were significantly different from baseline as soon as 1 week without 
BHT and 2 weeks with BHT. The -80C remained stable up to 12 weeks and showed no 
significant differences from baseline. The Mitra showed a similar pattern to the 903 PSC (Figure 
9). In brief, EPA + DHA concentrations were significantly different for 4 to 8 weeks with or 
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without BHT at ambient and 4C temperatures, 1 week without and 2 weeks with BHT at -20C 
and remained stable through 12 weeks both with and without BHT at -80C. 
The 903 PSC showed highest FA stability over 12 weeks when stored at -80C in 
comparison to baseline values and only showed significant differences in the total FAs category 
(Table 6). The relationship between time, the presence or absence of BHT and temperature 
showed significant differences at the -20C conditions. The highest differences from baseline 
were seen at the -20C condition without BHT (Table 6). There were significantly lower 
concentrations for most FAs in comparison to baseline; the total saturated fatty acids (SFAs), 
HUFA, PUFA, total n-6, total n-3, and total concentrations were all significantly lower in 
comparison to baseline values. Similarly, the Mitra FA profiles showed the most significant 
differences at -20C for most individuals FAs and biomarkers including total SFAs, HUFAs, 
PUFAs, total n-6, and total n-3 (Table 7).  
 
8.4 Discussion 
The fatty acids in the samples were the most stable at -80C, followed by 4C and 
ambient temperature, and the least stable at -20C in both BHT and no BHT conditions. The 
stability of the EPA + DHA and n-3 HUFA in total HUFA biomarker ratios were increased with 
the use of BHT in all conditions. The reason for the accelerated degradation at -20C is because 
of the hemolysis and iron-initiated peroxidation in RBCs [52] as the hemoglobin-iron complex 
(HB-Fe2+) can be converted into (HB-Fe3+) by O2 resulting in O2 free radical and Fe3+ formation 
which can interact with PUFAs and cause peroxidation and FA loss. This study supports the 
conclusions by Metherel et al. [52] stating that ambient and 4C storage conditions should be 
used if there is no access to -80C, if solely using BHT as a preservation agent. We also 
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confirmed that expressed omega-3 status data as the percentage of n-3 HUFA in total HUFA 
results in an omega-3 status that is more resistant to changes due to oxidation as the HUFA pool 
tends to degrade at a similar rate in comparison with data expresses relative to total fatty acids 
where the saturated and monounsaturated pools are much more stable [14]. 
The interaction effect involving collection material and time and antioxidant on the 
percentage of EPA+DHA was not anticipated.   This appears be driven in part by an increase in 
EPA + DHA measured in the Mitra after 1 week of storage with no BHT.  This seems to be a 
spurious result as an increase above baseline is unlikely.  In contrast, the EPA + DHA in 903 
PSC does not appear to change at week 1 with and without BHT while there is a slight decrease 
in Mitra with BHT. 
This study contributed to the literature by determining FA stability quantitatively on both 
903 PSC and the Mitra. Quantitative data is overall rather low in comparison to qualitative data 
for DBS due to the collection of unknown volumes so most FA stability information is presented 
in relative percentage. Iron chelators to prevent iron initiated oxidation, glucose to prevent cell 
lysis and BHT combined could improve FA stability at -20C [52]. However, using BHT alone 
shows biomarker stability from 4 to 8 weeks at both ambient and 4C conditions. Ultra-cold 
storage should be used whenever available as studies have shown biomarker stability for at least 
6 months at -75 C [14]. 
8.5 Conclusions, Limitations and Future Directions 
In conclusion, storage of DBS on 903 PSC and Mitra should be at ultra-cold temperatures 
such as -80C whenever possible.  If ultra-cold storage is not possible, ambient and 4C should 
be considered, while storage at -20C should be avoided. In addition, efforts should be made to 
add BHT to DBS samples to also prevent losses of PUFA to oxidation.  In the present study, 
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BHT was added to blood during collection, but this may not be possible for samples collected 
from capillary beds such as fingertip or heel prick. Further research is needed to determine if 
both 903 PSC and Mitra can be pretreated with BHT prior to blood collection. Both EPA + DHA 
and n-3 HUFA in total HUFA displayed similar behavior when considering stability over time. 
Similarly, to have reliable biomarker data, samples should be stored at -80C followed by 4C or 
ambient temperatures. The conditions reviewed in this study are applicable to field research and 
the potential storage limitations that may accompany it. Ultra-cold storage is generally limited to 
analytical facilities and therefore ambient, 4C and -20C were examined as alternatives.   
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Table 4 Relative percentage (% of total fatty acids) of EPA + DHA in 903 PSC and the Mitra during storage over 12 weeks.  
Material Condition Temperature Storage Day      
      Baseline 1w 2w 4w 8w 12w 
903 PSC No BHT Ambient 3.04 ± 0.65 3.01 ± 0.55 3.10 ± 0.42 3.05 ± 0.59 2.72 ± 0.44* 2.45 ± 0.51* 
  4ºC   3.12 ± 0.50  3.20 ± 0.39 2.99 ± 0.55 2.62 ± 0.32* 2.35 ± 0.41* 
  -20ºC  2.31 ± 0.44* 2.05 ± 0.40* 1.55 ± 0.38* 1.23 ± 0.44 * 1.01 ± 0.39* 
  -80ºC  3.01 ± 0.51 3.11 ± 0.34 3.05 ± 0.37 2.98 ± 0.41 2.99 ± 0.49 
 BHT Ambient 3.01 ± 0.51 3.00 ± 0.45 3.11 ± 0.41  3.06 ± 0.39 2.55 ± 0.43* 2.41 ± 0.40* 
  4ºC   3.11 ± 0.42 3.07 ± 0.34 3.01 ± 0.32 2.67 ± 0.42* 2.60 ± 0.30* 
  -20ºC  2.87 ± 0.36 2.57 ± 0.29* 2.44 ± 0.35* 2.11 ± 0.23* 2.01 ± 0.25*  
  -80ºC  3.12 ± 0.44 3.05 ± 0.34 2.99 ± 0.25 2.82 ± 0.42 2.85 ± 0.38 
Mitra No BHT Ambient 3.14 ± 0.35 3.31 ± 0.41 3.11 ± 0.34 2.99 ± 0.62 2.65 ± 0.44* 2.35 ± 0.41* 
  4ºC   3.22 ± 0.40  3.11 ± 0.33 3.01 ± 0.45 2.52 ± 0.31* 2.27 ± 0.31* 
  -20ºC  2.33 ± 0.34* 1.99 ± 0.37* 1.44 ± 0.39* 1.22 ± 0.42* 1.04 ± 0.32* 
  -80ºC  3.11 ± 0.52 3.01 ± 0.32 3.15 ± 0.40 2.97 ± 0.42 2.99 ± 0.51 
 BHT Ambient 3.10 ± 0.33 3.05 ± 0.39 3.15 ± 0.30 3.18 ± 0.29 2.65 ± 0.37* 2.48 ± 0.44* 
  4ºC   3.15 ± 0.32 3.01 ± 0.28 3.17 ± 0.26 2.52 ± 0.40* 2.41 ± 0.42* 
  -20ºC  2.91 ± 0.31 2.59 ± 0.33* 2.51 ± 0.35* 2.19 ± 0.39* 2.05 ± 0.45* 
    -80ºC  3.15 ± 0.38 3.08 ± 0.24  3.07 ± 0.29 3.17 ± 0.35 3.13 ± 0.34 
903 Protein Saver Cards (903 PSC); butylated hydroxytoluene (BHT); eicosapentaenoic acid (EPA); docosahexaenoic acid (DHA). 
Asterisk used to highlight significantly different values from baseline after one-way ANOVA + Dunnett’s test with p < 0.05. (n = 10). 
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Table 5 Relative percentage (% of total fatty acids) of omega-3 HUFA in total HUFA in 903 Protein Saver Cards and the Mitra 
during storage over 12 weeks.  
Material Condition Temperature Storage Day      
      Baseline 1w 2w 4w 8w 12w 
903 PSC No BHT Ambient 25.72 ± 1.58 25.06 ± 3.33 25.55 ± 2.15 25.45 ± 2.37 23.74 ± 2.09* 23.15 ± 1.38* 
  4°C  25.26 ± 3.11 25.45 ± 2.11 25.65 ± 2.12 23.77 ± 2.19* 25.28 ± 1.55 
  -20°C  25.84 ± 3.04 22.75 ± 1.93* 20.23 ± 1.82* 20.54 ± 2.45* 20.01 ± 1.67* 
  -80°C  25.46 ± 3.12 25.56 ± 2.14 26.55 ± 3.27 26.16 ± 3.23 25.96 ± 3.11 
 BHT Ambient 24.70 ± 2.13 25.02 ± 2.14 24.96 ± 2.11 24.88 ± 2.21 23.04 ± 2.32* 22.99 ± 1.01* 
  4°C  25.16 ± 3.01 24.51 ± 2.12 24.22 ± 2.13 22.99 ± 2.11* 22.91 ± 1.65* 
  -20°C  24.64 ± 3.01 24.46 ± 2.14 24.51 ± 1.45 22.45 ± 2.23* 22.56 ± 1.25* 
  -80°C  24.57 ± 2.01 24.45 ± 2.21 25.02 ± 3.12 24.77 ± 3.01 24.12 ± 3.23 
Mitra No BHT Ambient 24.59 ± 2.90 24.16 ± 3.11 24.44 ± 2.21 24.71 ± 1.19 23.44 ± 2.46* 23.56 ± 1.57* 
  4°C  24.56 ± 2.34 24.65 ± 2.14 24.55 ± 2.01 23.04 ± 2.54* 22.99 ± 1.26* 
  -20°C  24.33 ± 2.22 21.45 ± 1.59* 20.33 ± 1.57* 20.04 ± 2.10* 19.98 ± 1.47* 
  -80°C  24.61 ± 2.12 24.55 ± 2.11 24.81 ± 2.10 24.13 ± 2.45 25.12 ± 1.99 
 BHT Ambient 24.89 ± 2.11 24.88 ± 2.50 24.69 ± 2.01 24.66 ± 1.76 23.04 ± 2.10* 23.05 ± 1.05* 
  4°C  24.06 ± 3.11 24.44 ± 2.14 24.90 ± 1.89 23.01 ± 1.55* 23.10± 1.35* 
  -20°C  24.14 ± 2.11 24.54 ± 1.58 24.18 ± 1.04 22.13 ± 2.39* 22.59 ± 1.59* 
    -80°C   24.57 ± 2.14 24.59 ± 2.19 24.35 ± 1.66 25.01 ± 2.90 25.61 ± 3.21 
903 Protein Saver Cards (903 PSC); butylated hydroxytoluene (BHT); highly unsaturated fatty acid (HUFA) 
Asterisk used to highlight significantly different values from baseline after one-way ANOVA + Dunnett’s test with p < 0.05. (n = 10). 
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Figure 9. The effects of BHT on concentrations of EPA + DHA in blood spotted 903 PSC stored at ambient, 4C, -
20C and -80C storage temperatures over 12 weeks. Data presented in concentration (g FA/ mL blood). 
*Indicates EPA + DHA concentration significantly lower than baseline (day 0) as determined by Dunnett’s 
test following a significant F-value by one-way ANOVA. Data presented as means ± SD. EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid; BHT, butylated hydroxytoluene. 
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Figure 10. The effects of BHT on concentrations of EPA + DHA in the Mitra stored at ambient, 4C, -20C and -
80C storage temperatures over 12 weeks. Data presented in concentration (g FA/ mL blood). *Indicates EPA + 
DHA concentration significantly lower than baseline (day 0) as determined by Dunnett’s test following a 
significant F-value by one-way ANOVA. Data presented as means ± SD. EPA, eicosapentaenoic acid; DHA, 
docosahexaenoic acid; BHT, butylated hydroxytoluene.
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Table 6. Fatty acid concentrations for 903 PSC without BHT at baseline and  -20C and -80C 
at 12 weeks (μg FA/ mL of blood) 
 Baseline -20C @ 12w -80C @ 12w 
10:0 0.12 ± 0.10 0.10 ± 0.10 0.11 ± 0.09 
12:0 0.51 ± 0.26 0.19 ± 0.25* 0.48 ± 0.24 
14:0 2.38 ± 0.89 1.31 ± 0.87* 2.29 ± 0.82 
16:0 60.17 ± 13.26 42.88 ± 12.96* 57.82 ± 12.23* 
18:0 31.82 ± 3.21 16.61 ± 3.14* 30.63 ± 2.97 
20:0 1.11 ± 0.08 0.68 ± 0.08* 1.07 ± 0.08 
22:0 3.68 ± 0.27 3.16 ± 0.26 3.54 ± 0.25 
23:0 0.82 ± 0.17 0.76 ± 0.17 0.79 ± 0.16 
24:0 5.29 ± 1.07 3.43 ± 1.05* 5.11 ± 0.99 
SFAs 105.59 ± 16.17 71.29 ± 15.81* 101.63 ± 14.92 
12:1 0.07 ± 0.04 0.14 ± 0.04 0.07 ± 0.04 
14:1 0.13 ± 0.15 0.21 ± 0.15 0.13 ± 0.14 
16:1 2.82 ± 1.86 2.92 ± 1.82 2.71 ± 1.72 
18:1n-7 4.76 ± 1.01 4.95 ± 0.98 4.58 ± 0.93 
18:1n-9 50.15 ± 9.29 55.95 ± 9.09* 48.27 ± 8.58 
20:1n-9 0.71 ± 0.15 0.68 ± 0.14 0.69 ± 0.13 
22:1n-9 0.34 ± 0.15 0.29 ± 0.15 0.33 ± 0.14 
24:1n-9 5.45 ± 1.10 3.17 ± 1.08* 5.27 ± 1.02 
MUFAs 64.42 ± 12.36 67.09 ± 12.08 62.01 ± 11.40 
18:2n-6 64.53 ± 10.13 61.09 ± 9.90 62.12 ± 9.35 
18:3n-6 0.77 ± 0.34 0.49 ± 0.33* 0.74 ± 0.31 
20:2n-6 0.36 ± 0.51 1.53 ± 0.50* 0.34 ± 0.47 
20:3n-6 3.99 ± 1.38 2.88 ± 1.35* 3.86 ± 1.27 
20:4n-6 29.36 ± 4.98 18.91 ± 4.87* 28.26 ± 4.60 
22:2n-6 0.22 ± 0.21 2.42 ± 0.20* 0.21 ± 0.19 
22:4n-6 3.71 ± 0.84 2.09 ± 0.82* 3.57 ± 0.78 
22:5n-6 1.47 ± 0.84 1.43 ± 0.82 1.42 ± 0.77 
N-6 104.28 ± 14.66 86.32 ± 14.34* 100.37 ± 13.53 
18:3n-3 1.56 ± 0.56 1.21 ± 0.55 1.50 ± 0.52 
20:3n-3 0.15 ± 0.09 0.12 ± 0.09 0.14 ± 0.08 
20:5n-3 1.53 ± 0.53 1.05 ± 0.52* 1.48 ± 0.49 
22:5n-3 3.33 ± 0.60 1.69 ± 0.58* 3.22 ± 0.55 
22:6n-3 7.32 ± 2.14 2.43 ± 2.09* 7.04 ± 1.98 
N-3 13.88 ± 2.92 7.66 ± 2.86* 13.36 ± 2.70 
20:3n-9 0.67 ± 0.12 0.17 ± 0.12* 0.65 ± 0.11 
PUFAs 118.39 ± 16.89 93.05 ± 16.52* 113.96 ± 15.59 
HUFAs 48.24 ± 14.35 28.76 ± 14.03* 46.44 ± 13.24 
Total 288.97 ± 43.31 222.83 ± 42.36* 278.13 ± 39.98 
Data presented in concentration (μg FA/ mL of blood) means ± SD. FA, saturated fatty acids; MUFA, 
monounsaturated fatty acid, EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; PUFA, 
polyunsaturated fatty acid; HUFA, highly unsaturated fatty acid; n-3H/TH, n-3 HUFA in total HUFA, n = 
10. Asterisk used to highlight significantly different values (in comparison to baseline) after one-way ANOVA 
+ Dunnett’s test with p < 0.05.  
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Table 7. Fatty acid concentrations for Mitra without BHT at baseline and  -20C and -80C at 
12 weeks (μg FA/ mL of blood) 
 
Mitra  
Baseline 
Mitra  
-20C @ 12w 
Mitra  
-80C @ 12w 
10:0 0.65 ± 0.32 0.54 ± 0.29 0.61 ± 0.29 
12:0 0.91 ± 0.27 0.36 ± 0.25* 0.82 ± 0.25 
14:0 3.31 ± 0.95 1.86 ± 0.88* 3.12 ± 0.86 
16:0 65.26 ± 13.18 47.70 ± 12.25* 61.53 ± 11.98 
18:0 36.36 ± 3.45 19.44 ± 3.21* 34.30 ± 3.14 
20:0 0.99 ± 0.09 0.62 ± 0.09* 0.93 ± 0.09 
22:0 2.53 ± 0.29 2.22 ± 0.27* 2.39 ± 0.27 
23:0 0.57 ± 0.12 0.52 ± 0.11 0.53 ± 0.11 
24:0 4.84 ± 0.70 3.21 ± 0.65* 4.55 ± 0.63 
SFAs 115.27 ± 16.03 79.67 ± 14.90* 108.72 ± 14.58 
12:1 1.04 ± 0.88 2.31 ± 0.82* 0.98 ± 0.80 
14:1 0.11 ± 0.08 0.18 ± 0.08* 0.13 ± 0.08 
16:1 3.09 ± 2.02 3.24 ± 1.88 2.89 ± 1.84 
18:1n-7 5.01 ± 1.10 5.32 ± 1.02 4.723± 1.00 
18:1n-9 52.35 ± 11.37 59.82 ± 10.57* 49.38 ± 10.34 
20:1n-9 0.71 ± 0.10 0.74 ± 0.10 0.72 ± 0.09 
22:1n-9 1.66 ± 0.37 1.11 ± 0.35* 1.54 ± 0.34 
24:1n-9 5.33 ± 0.95 3.12 ± 0.88* 5.04 ± 0.87 
MUFAs 69.23 ± 13.81 71.93 ± 12.84 65.39 ± 12.56 
18:2n-6 64.34 ± 9.85 62.27 ± 9.16 60.69 ± 8.96* 
18:3n-6 0.72 ± 0.32 0.44 ± 0.30* 0.65 ± 0.29 
20:2n-6 0.17 ± 0.18 0.73 ± 0.17* 0.16 ± 0.17 
20:3n-6 4.05 ± 1.38 2.97 ± 1.28* 3.82 ± 1.25 
20:4n-6 29.40 ± 5.44 19.40 ± 5.06* 27.73 ± 4.95 
22:2n-6 0.13 ± 0.09 1.32 ± 0.08* 0.12 ± 0.08 
22:4n-6 3.72 ± 0.78 2.11 ± 0.73* 3.51 ± 0.71 
22:5n-6 2.21 ± 0.44 1.92 ± 0.41* 2.10 ± 0.40 
N-6 104.71 ± 15.19 88.75 ± 14.12* 98.77 ± 13.81 
18:3n-3 1.48 ± 0.57 1.27 ± 0.53* 1.38 ± 0.52 
20:3n-3 0.17 ± 0.13 0.11 ± 0.12* 0.17 ± 0.11 
20:5n-3 1.76 ± 0.54 1.22 ± 0.50* 1.67 ± 0.49 
22:5n-3 3.40 ± 0.61 1.74 ± 0.56* 3.20 ± 0.55 
22:6n-3 7.38 ± 2.13 2.05 ± 1.98* 6.95 ± 1.94 
N-3 14.16 ± 2.72 8.01 ± 2.53* 13.36 ± 2.47 
20:3n-9 0.67 ± 0.14 0.20 ± 0.13* 0.65 ± 0.13 
PUFAs 119.10 ± 17.36 95.85 ± 16.14* 112.31 ± 15.79 
HUFAs 52.46 ± 8.99 32.03 ± 8.36* 49.47 ± 8.17 
Total 304.11 ± 45.36 240.16 ± 42.18* 286.86 ± 41.25* 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acid, n-6, omega-6; n-3, omega-3; EPA, 
eicosapentaenoic acid; DHA, docosahexaenoic acid; PUFA, polyunsaturated fatty acid; HUFA, highly 
unsaturated fatty acid; n-3H/TH, n-3 HUFA in total HUFA, n = 10. Asterisk used to highlight 
significantly different values (in comparison to baseline) after one-way ANOVA + Dunnett’s test with p < 
0.05. Data presented in concentration (μg FA/ mL of blood) means ± SD. 
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Chapter 9 
General Discussion and Conclusion 
9.1 General Discussion 
Dried blood spot methods have many advantages when considering the tedious nature of 
handling wet blood and its related analytical procedures for fractioning especially for sample 
collection in field research circumstances. Most DBS FA profiles have been expressed in relative 
abundance or %TFA and FA concentrations are not possible due to the inability to quantitate the 
volume of blood collected. This thesis presented a method to quantitate blood and FA 
concentrations on commonly used 903 Protein Saver cards by determining a relationship 
between area and volume to create a predictive linear equation. As an alternative for blood 
quantitation on traditional DBS papers, FA analysis was performed on the Mitra. To supplement 
accurate quantitation, factors that that may influence quantitation, such as contaminants on blood 
collection material were identified and FA stability was determined at various storage 
temperatures with and without the addition of antioxidant. 
 In line with the stated hypothesis 1 (Chapter 3), a linear relationship was determined 
between the area of blood on the 903 PSC and volume applied which was then validated using 
the blood from ten individuals. The equation determined a blood volume of 9.6 μL when a 6mm 
punch was removed from a 903 PSC which was then used to confirm that accurate fatty acid 
concentrations could be determined from DBS on 903 PSC (hypothesis 2). Limitations may arise 
when considering how hematology can affect the blood and volume relationship on collection 
materials, therefore in the future, the DBS area/blood volume relationship on 903 PSC using 
blood samples with high or low hematocrit should be examined. As an alternative to dried blood 
spots, the 10 μL Mitra Microsampling Device that can collect accurate collections of volume 
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regardless of viscosity [60] was assessed and validated for the determination of fatty acid 
concentrations (hypothesis 3). While the fatty acid analyses of the Mitra were similar to wet 
blood controls, the lipidomics profile generally had lower recoveries in phospholipids and higher 
TAG and CE recoveries indicating that hypothesis 4 must be rejected at this time. However, the 
lipidomic profiles from the Mitra resembled a pattern similar initial attempts to perform 
lipidomics on DBS on other collection materials [46].  As such, the cause appears to be due to 
differences in the retention of polar and nonpolar lipids on the Mitra material.  The Mitra 
material, the three dimensional geometry of the Mitra tip and the wicking agents may be 
contributing to these differences in retention.  It is possible that Mitra derived lipidomic profiling 
could be improved using a tailored extraction procedure such as physical disruption of the Mitra 
and/or an acidified extraction protocol.  
Contaminants on commonly used dried spotting materials were identified to determine 
their influence on FA quantitation. In line with hypothesis 5, palmitate and stearate were found 
as lipid contaminants. Using UHPLC-MS/MS the form of the palmitate and stearate was as FFA 
in 903 PSC, Whatman chromatography paper and the Mitra, while the Mitra also had16:0 lysoPC 
and 18:0 lysoPC.  LysoPC or “lysolecithin” is used as an industrial emulsifying agent and could 
play a role in the Mitra’s wicking abilities.  FA and lipid contaminants on collection materials 
can be reduced through “washing” procedures.  In the case of the Mitra, washing could potential 
impact the wicking ability.   Overall, the impact of 16:0 and 18:0 contaminants would be small 
as the concentration of these FA contaminants on the materials was very low (0.97±0.08 μg of 
16:0 and 1.43±0.16 μg of 18:0 per 6mm punch of Whatman CP, 0.64±0.05 μg of 16:0 and 
0.88±0.04 18:0 per 6mm punch of 903 PSC and 0.80±0.08 μg 16:0 and 0.98±0.10 μg 18:0 per 
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Mitra tip) in comparison to their amounts of 16:0 and 18:0 in total lipids of whole blood samples 
(58.54±13.61 and 32.37±7.47 respectively, n=10).  
Optimal storage conditions for FA stability using 903 PSC and the Mitra were also examined. 
The storage experiment results were generally in line with the stated hypotheses (Chapter 3). In 
short, the HUFA status of DBS samples decreased in the Mitra and 903 PSC during storage 
(hypothesis 6), HUFA in DBS were the most stable when stored at -80C and the least stable at  -
20C (hypothesis 7), and the addition of BHT increased the stability of HUFA in all the DBS 
samples (hypothesis 8).  These results confirm previous reports in the literature for the storage of 
DBS on chromatography paper [14, 15].   
Steps can be taken to improve the studies discussed in this thesis. The 903 PSC and Mitra 
should be tested on other populations including children, elderly, malnourished individuals and 
individuals in postprandial states as further validation is required with high and low hematocrit 
blood. Tailoring the extraction procedure for the Mitra could provide higher overall lipid 
recoveries and as lipidomics is an emerging field of research, alternatives to wet blood should be 
considered and further tested. The presence of SFAs in low abundance does not have a large impact 
in comparison to the SFAs present in blood samples. To further assess the interferences of  FA 
contaminants on quantitation, all materials and solvents involved (gloves, glassware, hexane, 
water, BF3, etc.) should be tested for contaminants as well. The FA stability of samples at -20C 
can be improved using iron chelators, glycerol, vacuum sealing and antioxidants. However, BHT 
alone can provide biomarker stability from 4 to 8 weeks at both ambient and 4C.  
9.1 Conclusion 
  This thesis set out to address three main limitations in DBS which were blood and FA 
quantitation, the presence of spotting material contaminants and storage/handling conditions 
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which may lead to sample oxidation. Dried blood quantitation on 903 PSC and the Mitra were 
used to provide means to collect a quantifiable volume of blood which could be used in field 
research circumstances. Biological variates were used to confirm these methods but all blood 
was collected from healthy adults attending the University of Waterloo with relatively normal 
hematocrit content. The Mitra was validated FA analysis but lipidomics analysis still requires 
additional research to determine an ideal extraction procedure. Additionally, other factors that 
may interfere with DBS FA quantitation such as contaminants and FA stability in various storage 
conditions were identified. Cumulatively, these findings indicate that the limitations associated 
with fatty acid analysis of DBS can be improved and validated in the future and enable low cost 
and high throughput analyses in laboratory and field settings.   
 58 
 
References 
 
1. Zhang, P.Y., Role of omega-3 Fatty Acids in Cardiovascular Disease. Cell Biochem 
Biophys, 2015. 72(3): p. 869-75. 
2. Lapillonne, A. and S.J. Moltu, Long-Chain Polyunsaturated Fatty Acids and Clinical 
Outcomes of Preterm Infants. Ann Nutr Metab, 2016. 69 Suppl 1: p. 35-44. 
3. Bisgaard, H., et al., Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma 
in Offspring. N Engl J Med, 2016. 375(26): p. 2530-9. 
4. Stark, K.D., et al., Global survey of the omega-3 fatty acids, docosahexaenoic acid and 
eicosapentaenoic acid in the blood stream of healthy adults. Prog Lipid Res, 2016. 63: p. 
132-52. 
5. Harris, W.S., The omega-3 index as a risk factor for coronary heart disease. American 
Journal of Clinical Nutrition, 2008. 87(6): p. 1997s-2002s. 
6. Stark, K.D., et al., Translating plasma and whole blood fatty acid compositional data into 
the sum of eicosapentaenoic and docosahexaenoic acid in erythrocytes. Prostaglandins 
Leukotrienes and Essential Fatty Acids, 2016. 104: p. 1-10. 
7. Armstrong, J.M., A.H. Metherel, and K.D. Stark, Direct microwave transesterification of 
fingertip prick blood samples for fatty acid determinations. Lipids, 2008. 43(2): p. 187-
96. 
8. Agostoni, C., et al., Whole blood fatty acid composition at birth: From the maternal 
compartment to the infant. Clinical Nutrition, 2011. 30(4): p. 503-505. 
9. Agostoni, C., et al., Reduced docosahexaenoic acid synthesis may contribute to growth 
restriction in infants born to mothers who smoke. Journal of Pediatrics, 2005. 147(6): p. 
854-856. 
10. Mashavave, G., et al., Dried blood spot omega-3 and omega-6 long chain 
polyunsaturated fatty acid levels in 7-9 year old Zimbabwean children: a cross sectional 
study. Bmc Clinical Pathology, 2016. 16. 
11. Metherel, A.H., J.M. Armstrong, and K.D. Stark, Weekly changes in finger-tip prick 
blood highly unsaturated fatty acid (HUFA) composition with acute fish oil 
supplementation and washout in men and women. Faseb Journal, 2007. 21(5): p. A338-
A339. 
12. Rise, P., et al., Fatty acid profiles of blood lipids in a population group in Tibet: 
correlations with diet and environmental conditions. Asia Pac J Clin Nutr, 2008. 17(1): p. 
80-5. 
13. Metherel, A.H., et al., Butylated hydroxytoluene can protect polyunsaturated fatty acids 
in dried blood spots from degradation for up to 8 weeks at room temperature. Lipids in 
Health and Disease, 2013. 12. 
14. Metherel, A.H., J.J.A. Henao, and K.D. Stark, EPA and DHA Levels in Whole Blood 
Decrease More Rapidly when Stored at -20 degrees C as Compared with Room 
Temperature, 4 and -75 degrees C. Lipids, 2013. 48(11): p. 1079-1091. 
15. Metherel, A.H., et al., Butylated hydroxytoluene can protect polyunsaturated fatty acids 
in dried blood spots from degradation for up to 8 weeks at room temperature. Lipids 
Health Dis, 2013. 12: p. 22. 
16. Harris, W.S. and C. Von Schacky, The Omega-3 Index: a new risk factor for death from 
coronary heart disease? Prev Med, 2004. 39(1): p. 212-20. 
 59 
 
17. Stark, K.D., The percentage of n-3 highly unsaturated fatty acids in total HUFA as a 
biomarker for omega-3 fatty acid status in tissues. Lipids, 2008. 43(1): p. 45-53. 
18. Hodson, L., C.M. Skeaff, and B.A. Fielding, Fatty acid composition of adipose tissue and 
blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res, 2008. 
47(5): p. 348-80. 
19. Liu, G., B.S. Muhlhausler, and R.A. Gibson, Evaluation of contamination associated with 
current blood spot technology for determining the fatty acid status of individuals. 
European Journal of Lipid Science and Technology, 2015. 117(8): p. 1280-1286. 
20. Metherel, A.H., J.J. Aristizabal Henao, and K.D. Stark, EPA and DHA levels in whole 
blood decrease more rapidly when stored at -20 degrees C as compared with room 
temperature, 4 and -75 degrees C. Lipids, 2013. 48(11): p. 1079-91. 
21. Baack, M.L., et al., What is the relationship between gestational age and 
docosahexaenoic acid (DHA) and arachidonic acid (ARA) levels? Prostaglandins 
Leukotrienes and Essential Fatty Acids, 2015. 100: p. 5-11. 
22. Lauritzen, L., et al., DHA Effects in Brain Development and Function. Nutrients, 2016. 
8(1). 
23. Reed, G.W., et al., Treatment of Rheumatoid Arthritis with Marine and Botanical Oils: 
An 18-Month, Randomized, and Double-Blind Trial. Evidence-Based Complementary 
and Alternative Medicine, 2014. 
24. Grosso, G., et al., Role of omega-3 fatty acids in the treatment of depressive disorders: a 
comprehensive meta-analysis of randomized clinical trials. PLoS One, 2014. 9(5): p. 
e96905. 
25. Calder, P.C., Omega-3 fatty acids and inflammatory processes. Nutrients, 2010. 2(3): p. 
355-74. 
26. Trikalinos, T.A., et al., in Effects of Eicosapentanoic Acid and Docosahexanoic Acid on 
Mortality Across Diverse Settings: Systematic Review and Meta-Analysis of Randomized 
Trials and Prospective Cohorts: Nutritional Research Series, Vol. 4. 2012: Rockville 
(MD). 
27. Siscovick, D.S., et al., Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation 
and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the 
American Heart Association. Circulation, 2017. 135(15): p. e867-e884. 
28. Kris-Etherton, P.M., J.A. Grieger, and T.D. Etherton, Dietary reference intakes for DHA 
and EPA. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009. 81(2-3): p. 99-
104. 
29. Patterson, A.C., et al., Omega-3 polyunsaturated fatty acid blood biomarkers increase 
linearly in men and women after tightly controlled intakes of 0.25, 0.5, and 1 g/d of EPA 
+ DHA. Nutr Res, 2015. 35(12): p. 1040-51. 
30. Hegele, R.A., Plasma lipoproteins: genetic influences and clinical implications. Nat Rev 
Genet, 2009. 10(2): p. 109-21. 
31. Salonen, J.T., et al., HDL, HDL2, and HDL3 subfractions, and the risk of acute 
myocardial infarction. A prospective population study in eastern Finnish men. 
Circulation, 1991. 84(1): p. 129-39. 
32. Metherel, A.H. and K.D. Stark, The stability of blood fatty acids during storage and 
potential mechanisms of degradation: A review. Prostaglandins Leukot Essent Fatty 
Acids, 2016. 104: p. 33-43. 
 60 
 
33. Stark, K., Analytical implications of routine clinical testing for omega-3 fatty acid 
biomarkers. Lipid Technology, 2008. 20(8): p. 177-179. 
34. Scriver, C.C., A simple phenylalanine method for detecting phenylketonuria in large 
populations of newborn infants, by Robert Guthrie and Ada Susi, Pediatrics, 
1963;32:318-343. Pediatrics, 1998. 102(1 Pt 2): p. 236-7. 
35. Ichihar, K., et al., A convenient method for determination of the C20-22 PUFA 
composition of glycerolipids in blood and breast milk. Lipids, 2002. 37(5): p. 523-6. 
36. Marangoni, F., C. Colombo, and C. Galli, A method for the direct evaluation of the fatty 
acid status in a drop of blood from a fingertip in humans. World Rev Nutr Diet, 2005. 94: 
p. 139-43. 
37. Min, Y.J., et al., Effect of storage temperature and length on fatty acid composition of 
fingertip blood collected on filter paper. Prostaglandins Leukotrienes and Essential Fatty 
Acids, 2011. 84(1-2): p. 13-18. 
38. Bell, J.G., et al., Using a fingertip whole blood sample for rapid fatty acid measurement: 
method validation and correlation with erythrocyte polar lipid compositions in UK 
subjects. British Journal of Nutrition, 2011. 106(9): p. 1408-1415. 
39. Stokol, T. and D.V. Nydam, Effect of anticoagulant and storage conditions on bovine 
nonesterified fatty acid and beta-hydroxybutyrate concentrations in blood. J Dairy Sci, 
2005. 88(9): p. 3139-44. 
40. Stark, K.D.a.S., N., Jr., Fast gas chromatography for the identification of fatty acid 
methyl esters from mammalian samples. 2005. 
41. Masood, A., K.D. Stark, and N. Salem, Jr., A simplified and efficient method for the 
analysis of fatty acid methyl esters suitable for large clinical studies. J Lipid Res, 2005. 
46(10): p. 2299-305. 
42. Metherel, A.H., et al., Omega-3 polyunsaturated fatty acid profiling using fingertip-prick 
whole blood does not require overnight fasting before blood collection. Nutrition 
Research, 2012. 32(8): p. 547-556. 
43. Marangoni, F., C. Colombo, and C. Galli, A method for the direct evaluation of the fatty 
acid status in a drop of blood from a fingertip in humans: applicability to nutritional and 
epidemiological studies. Anal Biochem, 2004. 326(2): p. 267-72. 
44. Leo M.L. Nollet, F.T., Handbook of Analysis of Active Compounds in Functional Foods, 
ed. C. Press. 2012. 956. 
45. Sheppard, A.J. and J.L. Iverson, Esterification of Fatty-Acids for Gas-Liquid-
Chromatographic Analysis. Journal of Chromatographic Science, 1975. 13(9): p. 448-
452. 
46. Henao, J.J.A., et al., Tailored Extraction Procedure Is Required To Ensure Recovery of 
the Main Lipid Classes in Whole Blood When Profiling the Lipidome of Dried Blood 
Spots. Analytical Chemistry, 2016. 88(19): p. 9391-9396. 
47. McKenney, J.M. and D. Sica, Role of prescription omega-3 fatty acids in the treatment of 
hypertriglyceridemia. Pharmacotherapy, 2007. 27(5): p. 715-28. 
48. Elmehdawi, R., Hypolipidemia: a word of caution. Libyan J Med, 2008. 3(2): p. 84-90. 
49. Greene, H.L., L.L. Swift, and H.R. Knapp, Hyperlipidemia and fatty acid composition in 
patients treated for type IA glycogen storage disease. J Pediatr, 1991. 119(3): p. 398-403. 
50. Cala, M.P. and R.J. Meesters, Comparative study on microsampling techniques in 
metabolic fingerprinting studies applying gas chromatography-MS analysis. Bioanalysis, 
2017. 9(17): p. 1329-1340. 
 61 
 
51. Heussner, K., et al., Adhesive blood microsampling systems for steroid measurement via 
LC-MS/MS in the rat. Steroids, 2017. 120: p. 1-6. 
52. Metherel, A.H. and K.D. Stark, Cryopreservation Prevents Iron-Initiated Highly 
Unsaturated Fatty Acid Loss during Storage of Human Blood on Chromatography Paper 
at-20 degrees C. Journal of Nutrition, 2015. 145(3): p. 654-660. 
53. Hewawasam, E.L., G. Gibson, R. Muhlhausler, B., stimation of the Volume of Blood in a 
Small Disc Punched From a Dried Blood Spot Card. Lipid Science and Technology, 
2017. 
54. Phenomenex, Mitra Microsampling Device. 2014: Torrance, CA. 
55. Folch, J., M. Lees, and G.H. Sloane Stanley, A simple method for the isolation and 
purification of total lipides from animal tissues. J Biol Chem, 1957. 226(1): p. 497-509. 
56. Pichot, R., R.L. Watson, and I.T. Norton, Phospholipids at the Interface: Current Trends 
and Challenges. International Journal of Molecular Sciences, 2013. 14(6): p. 11767-
11794. 
57. Bandyapadhyay, G.K. and J. Dutta, Separation of methyl esters of polyunsaturated fatty 
acids by argentation thin-layer chromatography. J Chromatogr, 1975. 114(1): p. 280-2. 
58. Koulman, A., et al., The development and validation of a fast and robust dried blood spot 
based lipid profiling method to study infant metabolism. Metabolomics, 2014. 10(5): p. 
1018-1025. 
59. Prentice, P., et al., Lipidomic analyses, breast- and formula-feeding, and growth in 
infants. J Pediatr, 2015. 166(2): p. 276-81 e6. 
60. Spooner, N., et al., A device for dried blood microsampling in quantitative bioanalysis: 
overcoming the issues associated blood hematocrit. Bioanalysis, 2015. 7(6): p. 653-9. 
 
